Methods and compositions for the treatment of non-muscle-invasive bladder cancer (NMIBC)

A PD-L1 antibody combined with BCG therapy effectively addresses high recurrence rates in NMIBC by enhancing DFS and OS, offering a promising alternative to traditional BCG treatments.

WO2026234281A1PCT designated stage Publication Date: 2026-11-12ASTRAZENECA AB
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2026/063511
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-09
Filing Date
2026-05-08
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current treatments for non-muscle-invasive bladder cancer (NMIBC) using bacillus Calmette-Guerin (BCG) therapy have high recurrence rates, with limited alternatives for patients who fail BCG, necessitating a need for innovative therapies to reduce recurrence and progression.

Method used

A combination therapy comprising a PD-L1 antibody, such as durvalumab, administered every 28 days for 13 cycles, combined with BCG induction and maintenance therapies to treat NMIBC.

Benefits of technology

The combination therapy significantly improves disease-free survival (DFS) and overall survival (OS) in patients with NMIBC, reducing recurrence and progression rates compared to BCG alone, without increasing BCG toxicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000056_0001
    Figure IMGF000056_0001
  • Figure IMGF000056_0002
    Figure IMGF000056_0002
  • Figure IMGF000056_0003
    Figure IMGF000056_0003
Patent Text Reader

Abstract

The disclosure relates to methods and compositions for treating patients with non-muscle-invasive bladder cancer using a combination therapy comprising a PD-L1 antibody (for example, durvalumab) and a bacillus Calmette-Guerin (BCG) treatment.
Need to check novelty before this filing date? Find Prior Art

Description

Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265METHODS AND COMPOSITIONS FOR THE TREATMENT OF NON-MUSCLE-INVASIVE BLADDER CANCER (NMIBC)CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims the benefit of priority to U.S. Provisional Application No: 63 / 802,865, filed May 9, 2025, which is incorporated by reference herein in its entirety for all purposes.REFERENCE TO SEQUENCE LISTING

[0002] The instant application contains an electronic Sequence Listing that has been submitted electronically and is hereby incorporated-by-reference in its entirety. The sequence listing was created on April 13, 2026, is named “24-1098-WO_Sequence-Listing.xml” and is 8,265 bytes in size.FIELD OF THE DISCLOSURE

[0003] The present disclosure relates to methods and compositions for treating patients with non-muscle-invasive bladder cancer using a combination therapy comprising a PD-L1 antibody and a bacillus Calmette-Guerin (BCG) therapy.BACKGROUND

[0004] The worldwide age-standardized incidence rate for bladder cancer (per 100,000 person / years) is 9.0 for men and 2.2 for women (GLOBOCAN 2012). In Europe, an estimated 151,297 new cases of bladder cancer were diagnosed in 2012, with an age-standardized incidence rate (per 100,000 persons) of 17.7 for males and 3.5 for females (GLOBOCAN 2012). In Europe, the age-standardized incidence rate for bladder cancer (per 100,000 person / years) is 19.1 for men and 4.0 for women, with the highest age-standardized incidence rate reported in Belgium (31 in men and 6.2 in women) and the lowest in Finland (18.1 in men and 4.3 in women). Worldwide, the bladder cancer age-standardized mortality rate (per 100,000 person / years) was 3.2 for men and 0.9 for women in 2012 (GLOBOCAN 2012).

[0005] Approximately 90% of urothelial tumors originate in the urinary bladder, 8% originate in the renal pelvis, and 2% originate in the ureter and urethra (National Comprehensive Cancer Network 2016). Urothelial carcinoma (UC), also known as transitional cell carcinoma (TCC), is the most common type of cancer of the bladder, ureter, urethra, and urachus, and accounts for approximately 90% of primary malignancies of the urinary tract.Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265

[0006] Bladder cancer is generally divided into muscle-invasive and non-muscle-invasive disease based on invasion of the muscularis propria. At the initial diagnosis of bladder cancer, 70% of cases are diagnosed as non-muscle-invasive bladder cancer (NMIBC) and approximately 30% as muscle-invasive bladder cancer (MIBC) (Babjuk et al 2017; Boccardo and Palmeri 2006). Non-muscle-invasive tumors consist of one of the following: noninvasive papillomas, carcinomas (Ta), tumors invading the lamina propria (Tl), and noninvasive flat carcinoma (Tis), also termed carcinoma in situ (CIS) (National Comprehensive Cancer Network 2016).

[0007] Categorizing an individual NMIBC patient’s risk for recurrence and progression is important for clinical management. The updated European Association of Urology guidelines for NMIBC categorize high-risk tumors as those having any of the following (Babjuk et al 2017): Tl tumor; High grade / histologic grade (G)3 tumor; CIS; Multiple and recurrent and large (with diameter of largest tumor >3 cm) tumors.

[0008] In NMIBC, approximately 70% of patients present as Ta, 20% as Tl, and 10% with CIS lesions (van Rhijn et al 2009). Recurrence (in 80% of NMIBC patients) is the main challenge for pTa patients, whereas progression (in 45% of NMIBC patients) is the main threat in pTl and CIS. In a recent European Organization for Research and Treatment of Cancer (EORTC) analysis, multiplicity, tumor size, and prior recurrence rate were the most important variables for recurrence, while tumor grade, stage, and presence of CIS were the most important variables for progression (Babjuk et al 2008; Sylvester et al 2006).

[0009] A treatment for patients with high-risk tumors, with the goal of reducing recurrence and preventing progression, is transurethral resection of bladder tumor (TURBT) followed by intravesical administration of bacillus Calmette-Guerin (BCG) (National Comprehensive Cancer Network 2016; Bellmunt et al 2014).

[0010] A number of randomized clinical studies have demonstrated the efficacy of BCG in NMIBC. One study demonstrated a 50% complete remission rate with a median duration of response projected to be >48 months (De Jager et al 1991). In the SWOG study, there was a statistically significant difference in disease-free survival (DFS) time between the TICE® BCG treatment group (induction [weekly for 6 weeks, at 8 and 12 weeks] and maintenance [monthly for a total treatment duration of 1 year]) and mitomycin C treatment group. A third study did not demonstrate a significant difference in DFS among TICE® BCG (induction only), a second strain of BCG (BCG-RIVM [induction only]), and mitomycin C (TICE BCG label). A review of 6 randomized clinical studies demonstrated a 67% reduction in theAttorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265recurrence rate at 12 months in the BCG plus TURBT group compared to the TURBT alone group (Shelley et al 2000).

[0011] However, even with the use of BCG, recurrence rates are as high as 50% in first 3 years of follow-up (Lamm 1995; Lundholm et al 1996; Vegt etal 1995). The recurrence rate for some aggressive histologic subtypes is even higher (up to 74% [Jakse et al 1987]).Patients with BCG failure are unlikely to respond to further BCG therapy. Few alternative treatments exist after BCG treatment failure, and the EAU, NCCN, and American Urological Association guidelines recommend radical cystectomy in patients with high-risk disease failing intravesical therapy (Babjuk et al 2017; Lamm et al 2016).

[0012] Significant limitations remain in the treatment of NMIBC and there remains a significant unmet medical need for innovative, effective therapies for NMIBC that can significantly reduce recurrence and progression rates. The present invention aims to address this unmet need.SUMMARY

[0013] The disclosure provides a method of treating a patient identified as having nonmuscle-invasive bladder cancer (NMIBC), the method comprising administering to the patient a combination therapy comprising a PD-L1 antibody (for example, durvalumab) and a bacillus Calmette-Guerin (BCG) therapy.

[0014] In an aspect, this disclosure provides a method of treating a patient identified as having non-muscle-invasive bladder cancer (NMIBC), the method comprising administering to the patient a combination therapy comprising a PD-L1 antibody and a bacillus Calmette-Guerin (BCG) treatment, wherein the PD-L1 antibody is administered about every 28 days (Q4W).

[0015] In another aspect, this disclosure provides a method of increasing disease-free survival (DFS) and / or overall survival (OS) in a patient with non-muscle-invasive bladder cancer (NMIBC), the method comprising administering to the patient a combination therapy comprising a PD-L1 antibody and a bacillus Calmette-Guerin (BCG) treatment.

[0016] In some embodiments, the PD-L1 antibody is durvalumab, adebrelimab (SHR-1316), atezolizumab, avelumab, cosibelimab (CK-301), envafolimab, or sugemalimab (CS1001). In an embodiment, the PD-L1 antibody is durvalumab.

[0017] In some embodiments, the PD-L1 antibody is administered about every 28 days (Q4W). In certain embodiments, the PD-L1 antibody is administered about every 28 days (Q4W) for about 13 cycles or up to about 13 cycles. In certain embodiments, the PD-L1Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265antibody is administered about every 28 days (Q4W) for about 13 cycles or up to about 13 cycles.

[0018] In some embodiments, the BCG treatment is a BCG induction therapy administered about every 7 days (Q1W) for about 6 weeks. In certain embodiments, the method further comprises administering a BCG maintenance therapy. In certain embodiments, the BCG maintenance therapy comprises administering the BCG therapy at 3 months, 6 months, 12 months, 18 months, and 24 months. In certain embodiments, the BCG maintenance therapy comprises administering the BCG treatment about every 7 days for three consecutive weeks at about 3 months, 6 months, 12 months, 18 months, and 24 months.

[0019] In some embodiments, the PD-L1 antibody of the combination therapy comprises about 1000 to 2000 mg of durvalumab. In certain embodiments, the PD-L1 antibody of the combination therapy comprises about 1500 mg of durvalumab.

[0020] In another aspect, this disclosure provides a method of treating a patient identified as having non-muscle-invasive bladder cancer (NMIBC), the method comprising: administering to the patient about 1500 mg of durvalumab about every 4 weeks (Q4W) for about 13 cycles; administering to the patient a bacillus Calmette-Guerin (BCG) induction therapy about every 7 days (Q1W) for about 6 weeks; and administering to the patient a BCG maintenance therapy about every 7 days for three consecutive weeks at about 3 months, 6 months, 12 months, 18 months, and 24 months.

[0021] In some embodiments, the NMIBC is a high-risk tumor. In certain embodiments, the high-risk tumor is defined as one or more of the following: a T1 tumor; a high grade / G3 tumor; carcinoma in situ (CIS); and multiple, and recurrent, large (tumor diameter >3 cm) tumors; and / or having papillary disease with or without CIS.

[0022] In some embodiments, the methods as disclosed herein result in improvement in DFS and / or overall survival (OS) compared to the BCG induction therapy alone and / or the BCG induction therapy and the BCG maintenance therapy. In certain embodiments, the methods as disclosed herein result in a significant improvement in disease-free survival (DFS); and optionally an improvement in one or more of: disease-free survival at 12 months (DFS 12) of at least about 5%; disease-free survival at 24 months (DFS24) of at least about 5%; disease-free survival at 36 months (DFS36) of at least about 4%; and overall survival (OS).

[0023] In another aspect, this disclosure provides a combination therapy comprising a PD-L1 antibody and a bacillus Calmette-Guerin (BCG) treatment for use in treating non-muscle-invasive bladder cancer (NMIBC) in a patient in need thereof, wherein the PD-L1 antibody is administered about every 28 days (Q4W).Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265

[0024] In another aspect, this disclosure provides a combination therapy comprising a PD-L1 antibody and a bacillus Calmette-Guerin (BCG) treatment for use in increasing disease-free survival (DFS) and / or overall survival (OS) in a patient with non-muscle-invasive bladder cancer (NMIBC).

[0025] In some embodiments, the PD-L1 antibody is durvalumab, adebrelimab (SHR-1316), atezolizumab, avelumab, cosibelimab (CK-301), envafolimab, or sugemalimab (CS1001). In an embodiment, the PD-L1 antibody is durvalumab.

[0026] In some embodiments, the PD-L1 antibody is administered about every 28 days (Q4W). In certain embodiments, the PD-L1 antibody is administered about every 28 days (Q4W) for about 13 cycles or up to about 13 cycles. In certain embodiments, the PD-L1 antibody is administered about every 28 days (Q4W) for about 13 cycles or up to about 13 cycles.

[0027] In some embodiments, the BCG treatment is a BCG induction therapy administered about every 7 days (Q1W) for about 6 weeks. In certain embodiments, the method further comprises administering a BCG maintenance therapy. In certain embodiments, the BCG maintenance therapy comprises administering the BCG therapy at 3 months, 6 months, 12 months, 18 months, and 24 months. In certain embodiments, the BCG maintenance therapy comprises administering the BCG treatment about every 7 days for three consecutive weeks at about 3 months, 6 months, 12 months, 18 months, and 24 months.

[0028] In some embodiments, the PD-L1 antibody of the combination therapy comprises about 1000 to 2000 mg of durvalumab. In certain embodiments, the PD-L1 antibody of the combination therapy comprises about 1500 mg of durvalumab.

[0029] In another aspect, this disclosure provides a combination therapy for use in treating a patient identified as having non-muscle-invasive bladder cancer (NMIBC), wherein the combination therapy comprises: administering to the patient about 1500 mg of durvalumab about every 4 weeks (Q4W) for about 13 cycles; administering to the patient a bacillus Calmette-Guerin (BCG) induction therapy about every 7 days (Q1W) for about 6 weeks; and administering to the patient a BCG maintenance therapy about every 7 days for three consecutive weeks at about 3 months, 6 months, 12 months, 18 months, and 24 months.

[0030] In some embodiments of the combination therapy, the NMIBC is a high-risk tumor. In certain embodiments, the high-risk tumor is defined as one or more of the following: a T1 tumor; a high grade / G3 tumor; carcinoma in situ (CIS); and multiple, and recurrent, and large (tumor diameter >3 cm) tumors; and / or having papillary disease with or without CIS.Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265

[0031] In some embodiments of the combination therapy, the therapy results in improvement in DFS and / or overall survival (OS) compared to the BCG induction therapy alone and / or the BCG induction therapy and the BCG maintenance therapy. In certain embodiments, the methods as disclosed herein result in a significant improvement in disease-free survival (DFS); and optionally an improvement in one or more of: disease-free survival at 12 months (DFS 12) of at least about 5%; disease-free survival at 24 months (DFS24) of at least about 5%; disease-free survival at 36 months (DFS36) of at least about 4%; and overall survival (OS).

[0032] In another aspect, this disclosure provides for the use of a combination therapy comprising a PD-L1 antibody and a bacillus Calmette-Guerin (BCG) treatment for the manufacture of a medicament for treating non-muscle-invasive bladder cancer (NMIBC) in a patient in need thereof, wherein the PD-L1 antibody of the medicament is administered about every 28 days (Q4W).

[0033] In another aspect, this disclosure provides for the use of a combination therapy comprising a PD-L1 antibody and a bacillus Calmette-Guerin (BCG) treatment for the manufacture of a medicament for increasing disease-free survival (DFS) and / or overall survival (OS) in a patient with non-muscle-invasive bladder cancer (NMIBC).

[0034] In some embodiments, the PD-L1 antibody is durvalumab, adebrelimab (SHR-1316), atezolizumab, avelumab, cosibelimab (CK-301), envafolimab, or sugemalimab (CS1001). In an embodiment, the PD-L1 antibody is durvalumab.

[0035] In some embodiments, the PD-L1 antibody is administered about every 28 days (Q4W). In certain embodiments, the PD-L1 antibody is administered about every 28 days (Q4W) for about 13 cycles or up to about 13 cycles. In certain embodiments, the PD-L1 antibody is administered about every 28 days (Q4W) for about 13 cycles or up to about 13 cycles.

[0036] In some embodiments, the BCG treatment is a BCG induction therapy administered about every 7 days (Q1W) for about 6 weeks. In certain embodiments, the method further comprises administering a BCG maintenance therapy. In certain embodiments, the BCG maintenance therapy comprises administering the BCG therapy at 3 months, 6 months, 12 months, 18 months, and 24 months. In certain embodiments, the BCG maintenance therapy comprises administering the BCG treatment about every 7 days for three consecutive weeks at about 3 months, 6 months, 12 months, 18 months, and 24 months.Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265

[0037] In some embodiments, the PD-L1 antibody of the combination therapy comprises about 1000 to 2000 mg of durvalumab. In certain embodiments, the PD-L1 antibody of the combination therapy comprises about 1500 mg of durvalumab.

[0038] In another aspect, this disclosure provides for the use of a durvalumab and a bacillus Calmette-Guerin (BCG) treatment in the manufacture of a medicament for treating nonmuscle-invasive bladder cancer (NMIBC) in a combination therapy, wherein the combination therapy comprises: administering to the patient about 1500 mg of durvalumab about every 4 weeks (Q4W) for about 13 cycles; administering to the patient a bacillus Calmette-Guerin (BCG) induction therapy about every 7 days for about 6 weeks; and administering to the patient a BCG maintenance therapy about every 7 days for three consecutive weeks at about 3 months, 6 months, 12 months, 18 months, and 24 months.

[0039] In some embodiments of the use, the NMIBC is a high-risk tumor. In certain embodiments, the high-risk tumor is defined as one or more of the following: a T1 tumor; a high grade / G3 tumor; carcinoma in situ (CIS); and multiple, and recurrent, and large (tumor diameter >3 cm) tumors; and / or having papillary disease with or without CIS.

[0040] In some embodiments, the uses as disclosed herein result in improvement in DFS and / or overall survival (OS) compared to the BCG induction therapy alone and / or the BCG induction therapy and the BCG maintenance therapy. In certain embodiments, the uses as disclosed herein result in a significant improvement in disease-free survival (DFS); and optionally an improvement in one or more of: disease-free survival at 12 months (DFS 12) of at least about 5%; disease-free survival at 24 months (DFS24) of at least about 5%; disease-free survival at 36 months (DFS36) of at least about 4%; and overall survival (OS).

[0041] In summary, patients with NMIBC benefit from treatment with a PD-L1 antibody (e.g., an anti-PD-Ll antibody, such as durvalumab) in combination with BCG therapy. As shown in the Examples, treatment with durvalumab in combination with BCG therapy significantly improves DFS and OS in individuals with NMIBC compared to patients only treated with BCG. This was surprising considering how effective treatment with BCG only is. Furthermore, the addition of durvalumab did not impact exposure to BCG and did not increase BCG toxicity.BRIEF DESCRIPTION OF DRAWINGS

[0042] The accompanying drawings are included to provide a further understanding of the methods and compositions of the disclosure. The drawings illustrate one or moreAttorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265embodiments of the disclosure, and together with the description serve to explain the principles and operation of the disclosure.

[0043] FIG. 1 show a schematic of the overall study design. BCG, Bacillus Calmette-Guerin; CFU, Colony forming unit; CIS, Carcinoma in situ; G, Histologic grade; HG, High-grade; I, Induction; IP, Investigational Product; M, Maintenance; m, Months;NMIBC, Non-muscle-invasive bladder cancer; O,S Overall survival; PI, Principal Investigator; Q4W, Every 4 weeks; T, Tumor stage; Ta, Noninvasive papillary carcinoma; Tl, Tumors invading the lamina propria; and w, Weeks. DFS is defined as the time from the date of randomization until the date of first recurrence of high-risk disease or death.

[0044] FIG. 2 shows overall study flow chart. BCG, Bacillus Calmette-Guerin.

[0045] FIG. 3 shows a dosing scheme for treatment groups. For patients with persistent disease at 3 months, a single BCG re-induction must be administered weekly for 6 weeks. For patients assigned to receive BCG (induction and maintenance) as part of their assigned treatment regimen, re-induction will be followed by BCG maintenance that will be administered for 3 weekly doses at 6, 12, 18, and 24 months. If patients demonstrate BCG failure (do not demonstrate complete response) after re-induction, they must be discontinued from treatment. If a patient’s weight falls to 30 kg or below, the patient should receive weight-based dosing equivalent to 20 mg / kg of durvalumab Q4W until the weight improves to >30 kg, at which point the patient should start receiving the fixed dosing of durvalumab 1500 mg Q4W. If durvalumab dosing is delayed, the BCG treatment regimen will be maintained, and the total number of doses of durvalumab (13) will be maintained unless criteria for discontinuation of IP are met. In the case of dose delay of durvalumab, patients may receive a total of 13 doses of durvalumab, and it is acceptable for these doses to extend beyond the originally planned durvalumab treatment period. Patients may delay and subsequently resume BCG dosing per local standard clinical practice. If dosing must be delayed for reasons other than treatment-related toxicity, dosing will resume as soon as feasible. BCG dose delays will not affect durvalumab dosing. If durvalumab dosing is discontinued, patients will be permitted to continue on BCG. If BCG is discontinued, patients will be allowed to continue durvalumab treatment at the discretion of the treating physician. Durvalumab and BCG may be administered on the same day; durvalumab would be administered first, followed by BCG.

[0046] FIG.4 shows a statistically significant and clinically meaningful improvement in disease free survival (DFS) compared to a control arm. DFS is defined as the time to the first recurrence of high-risk disease (recurrence of high-risk NMIBC (high-grade Ta, Tl, or CIS),Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265presentation with MIBC and / or metastatic disease or persistent CIS at 6 months) or death (by any cause in the absence of recurrence).

[0047] FIG. 5 shows an improvement in overall survival (OS) compared to a control arm and rules out an OS detriment. OS is defined as the proportion of patients alive from the date of randomization until death due to any cause.

[0048] FIG. 6 shows that durvalumab + BCG (I+M) prevented early recurrences compared with BCG (I+M) alone.

[0049] FIG. 7 shows time to cystectomy showed a trend in favor of durvalumab + BCG (I+M) vs BCG (I+M), with fewer patients undergoing cystectomy, and a longer median time to cystectomy, compared with BCG (I+M) alone.

[0050] FIG. 8 shows that cystectomy -free survival showed a favorable trend for D+BCG (I+M) vs BCG (I+M).

[0051] FIG. 9A - 9B show that in patients with any papillary tumors or with papillary tumors only, there was a 39% and 44% reduction, respectively, in the risk of disease recurrence, progression or death with D+BCG (I+M) vs BCG (I+M).

[0052] FIG. 10A - 10C show that, in patients with T1 disease, there was a 45-52% reduction in the risk of disease recurrence, progression or death with D+BCG (I+M) vs BCG (I+M).

[0053] FIG. 11 shows that addition of durvalumab to BCG (I+M) had no detriment to overall survival across papillary tumor subgroups.

[0054] FIG. 12 shows the safety profile of D+BCG (I+M) in patients with papillary tumors only was consistent with the overall safety population.

[0055] FIG. 13 shows that the majority of immune-mediated AEs (imAEs) in the overall population were low grade and manageable and consistent with the mechanism of durvalumab.

[0056] FIG. 14 shows of patients who experienced immune-mediated AEs (imAEs), 66% had imAEs resolved (with or without sequalae) or resolving at the time of data cutoff.

[0057] Skilled artisans will appreciate that elements in the Figures are illustrated for simplicity and clarity and have not necessarily been drawn to scale. For example, the dimensions of some of the elements in the Figures can be exaggerated relative to other elements to help improve understanding of the embodiments of the present disclosure.DETAILED DESCRIPTION

[0058] The present disclosure relates to methods for treating non -muscle-invasive bladder cancer (NMIBC). This disclosure demonstrates that treatment with a combination therapyAttorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265comprising aPD-Ll antibody (e.g. durvalumab) and a bacillus Calmette-Guerin (BCG) therapy results in a significant improvement of disease free survival (DFS) and / or overall survival (OS). This disclosure also demonstrates that treatment with a combination therapy results in an improvement of disease-free survival at 12 months (DSF12), disease-free survival at 24 months (DSF24), disease-free survival at 36 months (DSF36), and / or overall survival (OS).

[0059] The disclosure provides a method of treating a patient identified as having nonmuscle-invasive bladder cancer (NMIBC), the method comprising administering to the patient a combination therapy comprising a PD-L1 antibody (for example, durvalumab) and a bacillus Calmette-Guerin (BCG) therapy.

[0060] As utilized in accordance with the disclosure, unless otherwise indicated, all technical and scientific terms shall be understood to have the same meaning as commonly understood by one of ordinary skill in the art.

[0061] The following references provide one of skill with a general definition of many of the terms used in this disclosure: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed. 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th Ed., R. Rieger etal. (eds.), Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991). As used herein, the following terms have the meanings ascribed to them below, unless specified otherwise.

[0062] As used herein, the terms "comprise" and "include" and variations thereof (e.g., "comprises," "comprising," "includes," and "including") will be understood to indicate the inclusion of a stated component, feature, element, or step or group of components, features, elements or steps but not the exclusion of any other component, feature, element, or step or group of components, features, elements, or steps. Any of the terms "comprising," "consisting essentially of," and "consisting of' may be replaced with either of the other two terms, while retaining their ordinary meanings.

[0063] Unless specifically stated or obvious from its context, the term "or" as used herein is understood to be inclusive. Unless specifically stated or obvious from context, the terms "a", "an", and "the" as used herein are understood to be singular or plural.

[0064] Ranges provided herein are understood to be shorthand for all of the values within the range, inclusive of the first and last stated values. For example, a range of 1 to 50 is understood to include any number, combination of numbers, or sub-range from the group consisting 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25,Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-26526, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50.

[0065] Unless specifically stated or obvious from context, as used herein, the term "about" is understood as within a range of normal tolerance in the art, for example within 2 standard deviations of the mean. The term "about" is understood to refer to within 5%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.1%, 0.05%, or 0.01% of the stated value. When particular values or compositions are provided in the application and claims, unless otherwise stated, the meaning of "about" or "comprising essentially of' should be assumed to be within an acceptable error range for that particular value or composition. Unless otherwise clear from context, all numerical values provided herein are modified by the term "about.".

[0066] Any compositions or methods provided herein can be combined with one or more of any of the other compositions and methods provided herein.

[0067] As described herein, any concentration range, percentage range, ratio range or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one tenth and one hundredth of an integer), unless otherwise indicated.

[0068] Units, prefixes, and symbols are denoted in their Systeme International de Unites (SI) accepted form. Numeric ranges are inclusive of the numbers defining the range. Unless otherwise indicated, nucleotide sequences are written left to right in 5' to 3' orientation.Amino acid sequences are written left to right in amino to carboxy termini orientation. The headings provided herein are not limitations of the various aspects of the disclosure, which can be had by reference to the specification as a whole. Accordingly, the terms defined immediately below are more fully defined by reference to the specification in its entirety.

[0069] As used herein, the terms "or" and "and / or" can describe multiple components in combination or exclusive of one another. For example, "x, y, and / or z" can refer to "x" alone, "y" alone, "z" alone, "x, y, and z," "(x and y) or z," "x or (y and z)," or "x or y or z."

[0070] As used herein, the terms "treat," "treatment," or "treating" when used in the context of treating cancer refer to reducing disease pathology, reducing or eliminating disease symptoms, promoting increased survival rates, and / or reducing discomfort. For example, treating can refer to the ability of a therapy when administered to a subject, to reduce disease symptoms, signs, or causes. Treating also refers to mitigating or decreasing at least one clinical symptom and / or inhibition or delay in the progression of the condition and / or prevention or delay of the onset of a disease or illness.Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265

[0071] As used herein, the terms "subject," "individual," or "patient," refer to any subject, particularly a mammalian subject, for whom diagnosis, prognosis, or therapy is desired. Mammalian subjects include, for example, humans, non -human primates, dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, bears, and so on. In some embodiments, the terms "patient" or "subject" may refer to a human. In some embodiments, the patient has not received prior intravesical BCG (is BCG-naive). In some embodiments, the patient has previously received BCG, but has stopped BCG therapy for more than 3 years (thus may be considered BCG-naive). In some embodiments, the patient has previously received transurethral resection of bladder tumor (TURBT). In some embodiments, the patient has received no prior systemic therapy for NMIBC. In certain embodiments, the subject has papillary disease. In certain embodiments, the subject has papillary disease with CIS. In certain embodiments, the subject has papillary disease without CIS. In certain embodiments, the subject has papillary disease with or without CIS (excluding pure CIS). In certain embodiments, the subject had a complete resection of a papillary disease (e.g., a T1 papillary disease, or high grade Ta / Tl / CIS papillary disease). In certain embodiments, the subject had TURBT to remove high-risk NMIBC. In certain embodiments, the patient has residual CIS after TURBT. In some embodiments, the patient has a performance status of 0 or 1 at screening as defined by the World Health Organization (WHO) / Eastem Cooperative Oncology Group (ECOG). In certain embodiments, the patient has no prior exposure to immune-mediated therapy of cancer including, but not limited to, other anti-CTLA-4 therapy, anti-PD-1 therapy, anti-PD-Ll therapy, and anti-programmed cell death ligand 2 antibodies. In some embodiments, patients who have been treated with anticancer vaccines are excluded.

[0072] Non-muscle invasive bladder cancer (NMIBC), formerly known as superficial bladder cancer, occurs when cancer cells are confined to the inner lining of the bladder and haven't spread to the muscle layer. NMIBC is a widely heterogeneous sub-classification of bladder cancer. Roughly 70% of all new cases of bladder cancer are classified as non-muscle invasive. Depending on tumor characteristics, the probability of recurrence for any given patient can range from 15% to 70% at 1 year. Risk stratification by American Urological Association (AU A) and European Association of Urology (EAU) guidelines or by using nomograms / risk calculators developed from clinical trial data can help inform patient treatment decisions but may not accurately classify all patients. Bladder cancer can be classified according to traditional American Joint Committee on Cancer (AJCC) TNM staging. In the absence of nodal (N stage) or distant metastases (M stage), depth of tumor invasion (T stage) is the most important determination to be made and can be dichotomizedAttorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265based on whether the tumor is invading into or beyond the muscularis propia (muscle-invasive bladder cancer, MIBC) or not (non-muscle-invasive bladder cancer, NMIBC). Currently, about 90% of bladder cancers are confined to the bladder wall layers and of all localized bladder cancers (<T2), 75% are non-muscle invasive (Tis, Ta, Tl). Tumors can further be classified according to histological grade (low or high).

[0073] The stages of non-muscle invasive bladder cancer can be determined by looking at how far tumors have grown into the bladder. There are 3 T stages of non-muscle invasive bladder cancer: (a) Tis or CIS (also called carcinoma in situ , (b) Ta; and (c) Tl. CIS or Tis refers to Carcinoma in situ refers to a flat tumor and means the cells are very early cancer cells in the inner layer of the bladder lining. The cancer cells look very abnormal and are likely to grow quickly. This is called high grade. Without any treatment, approximately 54% of patients with CIS progress to muscle-invasive disease. Ta refers to NMIBC tumor only in the innermost layer of the bladder lining. Tl refers to tumors invading subepithelial connective tissue and that have started to grow into the connective tissue beneath the bladder lining. When staging bladder cancer, doctors can also look at whether the cancer has spread to any lymph nodes (N stage), or other parts of the body (distant metastasis) like the bones, lungs or liver (M stage). Tumor definitions are provided by the European Association of Urology (EAU) guidelines. The updated European Association of Urology guidelines for NMIBC categorize high-risk tumors as those having any of the following (Babjuk et al 2017): Tl tumor; High grade / histologic grade (G)3 tumor; CIS; Multiple and recurrent and large (with diameter of largest tumor >3 cm) tumors (see Table 1).Table 1: Clinical composition of EAU NMIBC prognostic factor risk groups.Risk GroupLow Risk A primary, single, TaTl LG / G1 tumor < 3 cm in diameter without CIS in a patient < 70 years.A primary Ta LG / G1 tumor without CIS with at most ONE of the additional clinical risk factorsIntermediate Risk Patients without CIS who are not included in either the low-, high-, or very high-risk groupsHigh Risk All Tl HG / G3 without CIS, EXCEPT those included in the very high-risk groupAll CIS patients, EXCEPT those included in the very high-risk group Stage, grade with additional clinical risk factors:• Ta LG / G2 or T1G1, no CIS with all 3 risk factors• Ta HG / G3 or Tl LG, no CIS with at least 2 risk factors• T1G2 no CIS with at least 1 risk factorVery High Risk Stage, grade with additional clinical risk factors:• Ta HG / G3 and CIS with all 3 risk factors• T1G2 and CIS with at least 2 risk factors• Tl HG / G3 and CIS with at least 1 risk factorAttorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265• T1 HG / G3 no CIS with all 3 risk factorsFrom EAU guidelines on NMBIBC 2024.

[0074] The disclosure provides a method of treating a patient identified as having nonmuscle-invasive bladder cancer (NMIBC), the method comprising administering to the patient a combination therapy comprising a PD-L1 antibody (for example, durvalumab) and a bacillus Calmette-Guerin (BCG) therapy.

[0075] In an aspect, this disclosure provides a method of treating a patient identified as having non-muscle-invasive bladder cancer (NMIBC), the method comprising administering to the patient a combination therapy comprising a PD-L1 antibody and a bacillus Calmette-Guerin (BCG) treatment, wherein the PD-L1 antibody is administered about every 28 days (Q4W).

[0076] In another aspect, this disclosure provides a method of increasing disease-free survival (DFS) and / or overall survival (OS) in a patient with non-muscle-invasive bladder cancer (NMIBC), the method comprising administering to the patient a combination therapy comprising a PD-L1 antibody and a bacillus Calmette-Guerin (BCG) treatment.

[0077] In some embodiments, the PD-L1 antibody is durvalumab, adebrelimab (SHR-1316), atezolizumab, avelumab, cosibelimab (CK-301), envafolimab, or sugemalimab (CS1001). In an embodiment, the PD-L1 antibody is durvalumab.

[0078] In some embodiments, the PD-L1 antibody is administered about every 28 days (Q4W). In certain embodiments, the PD-L1 antibody is administered about every 28 days (Q4W) for about 13 cycles or up to about 13 cycles. In certain embodiments, the PD-L1 antibody is administered about every 28 days (Q4W) for about 13 cycles or up to about 13 cycles.

[0079] In some embodiments, the BCG treatment is a BCG induction therapy administered about every 7 days (Q1W) for about 6 weeks. In certain embodiments, the method further comprises administering a BCG maintenance therapy. In certain embodiments, the BCG maintenance therapy comprises administering the BCG therapy at 3 months, 6 months, 12 months, 18 months, and 24 months. In certain embodiments, the BCG maintenance therapy comprises administering the BCG treatment about every 7 days for three consecutive weeks at about 3 months, 6 months, 12 months, 18 months, and 24 months.

[0080] In some embodiments, the PD-L1 antibody of the combination therapy comprises about 1000 to 2000 mg of durvalumab. In certain embodiments, the PD-L1 antibody of the combination therapy comprises about 1500 mg of durvalumab.Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265

[0081] In another aspect, this disclosure provides a method of treating a patient identified as having non-muscle-invasive bladder cancer (NMIBC), the method comprising: administering to the patient about 1500 mg of durvalumab about every 4 weeks (Q4W) for about 13 cycles; administering to the patient a bacillus Calmette-Guerin (BCG) induction therapy about every 7 days (Q1W) for about 6 weeks; and administering to the patient a BCG maintenance therapy about every 7 days for three consecutive weeks at about 3 months, 6 months, 12 months, 18 months, and 24 months.

[0082] In some embodiments, the NMIBC is a high-risk tumor. In certain embodiments, the high-risk tumor is defined as one or more of the following: a T1 tumor; a high grade / G3 tumor; carcinoma in situ (CIS); and multiple, and recurrent, and large (tumor diameter >3 cm) tumors.

[0083] In some embodiments, the methods as disclosed herein result in improvement in DFS and / or overall survival (OS) compared to the BCG induction therapy alone and / or the BCG induction therapy and the BCG maintenance therapy. In certain embodiments, the methods as disclosed herein result in a significant improvement in disease-free survival (DFS); and optionally an improvement in one or more of: disease-free survival at 12 months (DFS 12) of at least about 5%; disease-free survival at 24 months (DFS24) of at least about 5%; disease-free survival at 36 months (DFS36) of at least about 4%; and overall survival (OS).

[0084] In another aspect, this disclosure provides a combination therapy comprising a PD-L1 antibody and a bacillus Calmette-Guerin (BCG) treatment for use in treating non-muscle-invasive bladder cancer (NMIBC) in a patient in need thereof, wherein the PD-L1 antibody is administered about every 28 days (Q4W).

[0085] In another aspect, this disclosure provides a combination therapy comprising a PD-L1 antibody and a bacillus Calmette-Guerin (BCG) treatment for use in increasing disease-free survival (DFS) and / or overall survival (OS) in a patient with non-muscle-invasive bladder cancer (NMIBC).

[0086] In another aspect, this disclosure provides a combination therapy for use in treating a patient identified as having non-muscle-invasive bladder cancer (NMIBC), wherein the combination therapy comprises: administering to the patient about 1500 mg of durvalumab about every 4 weeks (Q4W) for about 13 cycles; administering to the patient a bacillus Calmette-Guerin (BCG) induction therapy about every 7 days (Q1W) for about 6 weeks; and administering to the patient a BCG maintenance therapy about every 7 days for three consecutive weeks at about 3 months, 6 months, 12 months, 18 months, and 24 months.Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265

[0087] In another aspect, this disclosure provides for the use of a combination therapy comprising a PD-L1 antibody and a bacillus Calmette-Guerin (BCG) treatment for the manufacture of a medicament for treating non-muscle-invasive bladder cancer (NMIBC) in a patient in need thereof, wherein the PD-L1 antibody of the medicament is administered about every 28 days (Q4W).

[0088] In another aspect, this disclosure provides for the use of a combination therapy comprising a PD-L1 antibody and a bacillus Calmette-Guerin (BCG) treatment for the manufacture of a medicament for increasing disease-free survival (DFS) and / or overall survival (OS) in a patient with non-muscle-invasive bladder cancer (NMIBC).

[0089] In another aspect, this disclosure provides for the use of a durvalumab and a bacillus Calmette-Guerin (BCG) treatment in the manufacture of a medicament for treating non-muscle-invasive bladder cancer (NMIBC) in a combination therapy, wherein the combination therapy comprises: administering to the patient about 1500 mg of durvalumab about every 4 weeks (Q4W) for about 13 cycles; administering to the patient a bacillus Calmette-Guerin (BCG) induction therapy about every 7 days for about 6 weeks; and administering to the patient a BCG maintenance therapy about every 7 days for three consecutive weeks at about 3 months, 6 months, 12 months, 18 months, and 24 months.

[0090] Programmed Death Ligand 1 ("PD-L1") is part of a complex system of receptors and ligands that are involved in controlling T-cell activation. Its normal function is to regulate the balance between T-cell activation and tolerance through interaction with its two receptors: programmed death 1 (also known as PD-1 or CD279) and CD80 (also known as B7-1 or B7.1). PD-L1 is also expressed by tumors and acts at multiple sites to help tumors evade detection and elimination by the host immune system. PD-L1 is expressed in a broad range of cancers with a high frequency.

[0091] As used herein, the terms "PD-L1 antibody" and "anti-PD-Ll antibody" refer to polypeptides, binding proteins, antibodies, or antigen-binding fragments thereof that selectively bind a PD-L1 polypeptide. In some embodiments, a PD-L1 inhibitor can be a PD-L1 antibody. Exemplary anti-PD-Ll antibodies are described, for example, in U.S. Patent Nos. 8,779,108 and 9,493,565, which are incorporated herein by reference. In some embodiments, the anti-PD-Ll antibody is durvalumab, adebrelimab (SHR-1316), atezolizumab, avelumab, cosibelimab (CK-301), envafolimab, or sugemalimab (C SI 001). In some embodiments, the PD-L1 antibody is durvalumab.

[0092] As used herein, the term "durvalumab" refers to an antibody that selectively binds PD-L1 and blocks the binding of PD-L1 to the PD-1 and CD80 receptors. The durvalumabAttorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265antibody is disclosed in U.S. Patent No. 9,493,565 (referred to as "2.14H9OPT"), which is incorporated by reference herein in its entirety. The fragment crystallizable (Fc) domain of durvalumab contains a triple mutation in the constant domain of the IgGl heavy chain that reduces binding to the complement component Clq and the Fey receptors responsible for mediating antibody-dependent cell-mediated cytotoxicity ("ADCC"). In certain embodiments, the triple mutation refers to the IgGl Fc region comprising a L234F / L235E / P331S triple mutation (EU numbering; see also US 9,493,565). Durvalumab can relieve PD-L1 -mediated suppression of human T-cell activation in vitro and inhibits tumor growth in a xenograft model via a T-cell dependent mechanism. Amino acid sequences of durvalumab are as follows:Table 2 . Durvalumab sequencesMEDI4736 VL EIVLTQSPGTLSLSPGERATLSCRASQRVSSSYLAWYQQKPGQAPRLLIYDASSRATGIPDRFSGS GSGTDFTLTISRLEPEDFAVYYCQQYGSLPWTFGQGTKVEIK ( SEQ ID NO . 1 ) _ MEDI4736 VL CDR1RASQRVSSSYLA (SEQ ID NO . 2 )MEDI4736 VL CDR2DASSRAT ( SEQ ID NO . 3 )MEDI4736 VL CDR3QQYGSLPWT ( SEQ ID NO . 4 )MEDI4736 VH EVQLVESGGGLVQPGGSLRLSCAASGFTFSRYWMSWVRQAPGKGLEWVANIKQDGSEKYYVDSVKG RFTISRDNAKNSLYLQMNSLRAEDTAVYYCAREGGWFGELAFDYWGQGTLVTVSS (SEQ ID NO . 5 )MEDI4736 VH CDR1GFTFSRYWMS (SEQ ID NO . 6) _MEDI4736 VH CDR2NIKQDGSEKYYVDSVKG ( SEQ ID NO . 7 ) _MEDI4736 VH CDR3EGGWFGELAFDY (SEQ ID NO . 8 ) _

[0093] In some embodiments, the PD-L1 antibody (e.g., an anti-PD-Ll antibody) can be administered once about every 21 to 35 days for up to about 10 to 20 cycles. In certain embodiments, the PD-L1 antibody can be administered once about every 21 to 35 days for up to about 10, 20, 30, 40, or 50 cycles. In certain embodiments, the PD-L1 antibody can be administered once about every 21 to 35 days for up to about 13 cycles. In some embodiments, the PD-L1 antibody can be administered once about every 28 days (Q4W) for up to about 13 cycles. Follow-on doses can be administered at various time intervals depending on the patient's age, weight, clinical assessment, tumor burden, and / or other factors, including the judgment of the attending physician.

[0094] In some embodiments, the PD-L1 antibody of the combination therapy is durvalumab. In some embodiments, the combination therapy comprises about 1000 to 2000 mg ofAttorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265durvalumab. In some embodiments, the combination therapy comprises about 1500 mg of durvalumab. In some embodiments, the combination therapy comprises administering about 1000 mg to about 2000 mg durvalumab once about every 21 to 35 days for up to about 10 to 20 cycles. In some embodiments, the combination therapy comprises administering about 1000 mg to about 2000 mg durvalumab once about every 21 to 35 days for up to about 10, 20, 30, 40, or 50 cycles. In some embodiments, the combination therapy comprises administering about 1000 mg to about 2000 mg durvalumab once about every 21 to 35 days for up to about 13 cycles. In some embodiments, the combination therapy comprises administering about 1000 mg to about 2000 mg durvalumab once about every 28 days (Q4W) for up to about 13 cycles.

[0095] In some embodiments, a dosage of the PD-L1 antibody might range from about 0.0001 mg / kg, about 0.001 mg / kg, about 0.01 mg / kg, about 0.1 mg / kg, about 1 mg / kg, about 10 mg / kg to up to about 100 mg / kg, about 1000 mg / kg, about 10000 mg / kg or more, of the patient's body weight. In some embodiments, the dosage may be from about 0.0001 mg / kg to about 20 mg / kg, about 0.0001 mg / kg to about 10 mg / kg, about 0.0001 mg / kg to about 5 mg / kg, about 0.0001 mg / kg to about 2 mg / kg, 0.0001 mg / kg to about 1 mg / kg, about 0.0001 mg / kg to about 0.75 mg / kg, about 0.0001 mg / kg to about 0.5 mg / kg, about 0.0001 mg / kg to about 0.25 mg / kg, about 0.0001 mg / kg to about 0.15 mg / kg, about 0.0001 mg / kg to about 0.10 mg / kg, about 0.001 mg / kg to about 0.5 mg / kg, about 0.01 mg / kg to about 0.25 mg / kg or about 0.01 mg / kg to about 0.10 mg / kg of the patient's body weight. In some embodiments, the dosage may be from about 1 mg / kg to about 30 mg / kg, or about 10 mg / kg to about 20 mg / kg. Typically, a clinician will administer the therapeutic antibody until a dosage is reached that achieves the desired effect.

[0096] In some embodiments, the PD-L1 antibody is durvalumab and a dosage of durvalumab might range from about 0.0001 mg / kg, about 0.001 mg / kg, about 0.01 mg / kg, about 0.1 mg / kg, about 1 mg / kg, about 10 mg / kg to up to about 100 mg / kg, about 1000 mg / kg, about 10000 mg / kg or more, of the patient's body weight. In some embodiments, the dosage may be between about 0.0001 mg / kg and about 20 mg / kg, about 0.0001 mg / kg and about 10 mg / kg, about 0.0001 mg / kg and about 5 mg / kg, about 0.0001 mg / kg and about 2 mg / kg, 0.0001 mg / kg and about 1 mg / kg, about 0.0001 mg / kg and about 0.75 mg / kg, about 0.0001 mg / kg and about 0.5 mg / kg, about 0.0001 mg / kg to about 0.25 mg / kg, about 0.0001 mg / kg to about 0.15 mg / kg, about 0.0001 mg / kg to about 0.10 mg / kg, about 0.001 mg / kg to about 0.5 mg / kg, about 0.01 mg / kg to about 0.25 mg / kg or about 0.01 mg / kg to about 0.10 mg / kg of the patient's body weight. In some embodiments, the dosage of durvalumab mightAttorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265be from about 1 mg / kg to about 30 mg / kg, or about 10 mg / kg to about 20 mg / kg. Typically, a clinician will administer the therapeutic antibody until a dosage is reached that achieves the desired effect. In some embodiments, the combination therapy comprises administering about 10 mg / kg to about 20 mg / kg durvalumab once about every 28 days (Q4W) for up to about 13 cycles.

[0097] In some embodiments, if a patient's weight falls to 30 kg or below [<30 kg], the patient should receive weight-based dosing equivalent to about 20 mg / kg of durvalumab about Q4W until the weight improves to >30 kg, at which point the patient should start receiving a fixed dosing of durvalumab (for example, about 1500 mg about Q4W). Thus, in some embodiments, the combination therapy comprises administering about 20 mg / kg durvalumab once about every 28 days (Q4W) for up to about 13 cycles.

[0098] In some embodiments, durvalumab (MEDI4736) can be provided as a 500 mg vial solution for infusion after dilution. In some embodiments, the solution contains 50 mg / mL durvalumab, 26 mM histidine / histidine-hydrochloride, 275 mM trehalose dihydrate, and 0.02% w / v polysorbate 80; it has a pH of 6.0 and density of 1.054 g / mL. In certain embodiments, a dose of about 1500 mg (for patients >30 kg in weight) can be administered using an IV bag containing 0.9% (w / v) saline or 5% (w / v) dextrose, with a final durvalumab concentration ranging from 1 to 15 mg / mL and delivered through an IV administration set with a 0.2- or 0.22-pm filter. If patient weight falls to <30 kg, WT-based dosing at 20 mg / kg can be administered using an IV bag selected such that the final concentration is within 1 to 15 mg / mL. In some embodiments, a standard infusion time is 1 hour (±10 minutes); however, if there are interruptions, the total allowed time must not exceed 8 hours at room temperature.

[0099] Bacille Calmette-Guerin (BCG) is an intravesical therapy for treating non-muscle-invasive urothelial carcinoma. BCG is a live-attenuated strain of Mycobacterium bovis initially developed as a vaccine for tuberculosis, and the first published reports of its use in the bladder were in 1976. BCG may be locally sourced where possible and administered according to prescribing information or treatment guidance.

[0100] As used herein, “a BCG treatment” may refer to a BCG induction therapy, or both a BCG induction therapy and a BCG maintenance therapy.

[0101] As used herein, “a BCG induction therapy” can refer to an induction phase of sixweekly instillations (Q1W for 6 weeks). In some embodiments, a BCG induction therapy is the start of BCG treatment in a BCG naive patient or a patient who had not received a BCG treatment for at least three years.Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265

[0102] As used herein, “a BCG maintenance therapy” can refer to a phase of three, weekly instillations at 3, 6, 12, 18, 24, 30 and 36 months, respectively (i.e. one dose per week (about every 7 days) for three consecutive weeks, at months 3, 6, 12, 18, 24, 30, and 36). In some embodiments, the BCG maintenance therapy follows the BCG induction therapy. In some embodiments, the BCG treatment comprises a combination of the BCG induction therapy and the BCG maintenance therapy. In some embodiments, an intravesical dose of bacillus Calmette-Guerin (i.e., a BCG treatment) can be administered for one to three years.

[0103] In some embodiments, the BCG maintenance therapy follows the BCG induction therapy. In some embodiments, the BCG treatment comprises a combination of the BCG induction therapy and the BCG maintenance therapy.

[0104] A dose of BCG treatment can refer to 1 vial (i.e. 1-8 x 108colony forming units (CFU)) of BCG (e.g., 1 vial of TICE® BCG). For example, in some embodiments, a BCG treatment can comprise a BCG induction therapy, or both a BCG induction therapy and a BCG maintenance therapy, wherein each dose of the BCG treatment comprises 1 vial (i.e. 1-8 X 108colony forming units (CFU)) of BCG. In some embodiments, an alternative BCG strain can be used comprising an equivalent dose of local standard BCG strain (e.g. Tokyo for Japan and BCG-1 for Russia).

[0105] In some embodiments, the success of the combination therapy is determined by disease-free survival (DFS); disease-free survival at 12 months (DFS12); disease-free survival at 24 months (DFS24); disease-free survival at 36 months (DFS36); overall survival (OS); complete response rate (CRR); overall survival at 5 years (OS5); any disease-free survival (aDFS); improvement in time to MIBC and / or metastatic disease; or improvement in time to cystectomy.

[0106] In some embodiments, the success of the method of treatment is determined by an improvement in one or more of DFS or DFS24 compared to a standard of care or a BCG treatment (i.e., a BCG induction therapy and / or a BCG maintenance therapy).

[0107] In some embodiments, the success of the method of treatment is determined by an improvement in one or more of DFS, DFS 12, DFS24, or DFS36 compared to a standard of care or a BCG treatment (i.e., a BCG induction therapy and / or a BCG maintenance therapy). For example, the success of the method of treatment can be determined by an improvement in one or more of DFS, DFS12, DFS24, or DFS36 of at least about 4%, 5%, 6%, 7%, 8%, 9%, 10% or more compared to a control arm (e.g. BCG induction therapy and BCG maintenance therapy).Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265

[0108] In some embodiments, the success of the method of treatment is determined by an improvement in complete response rate (CRR) as compared to standard of care or a BCG treatment (i.e., a BCG induction therapy and / or a BCG maintenance therapy).

[0109] In some embodiments, the success of the method of treatment is determined by an improvement in overall survival (OS) or overall survival at 5 years (OS5) as compared to standard of care or a BCG treatment (i.e., a BCG induction therapy and / or a BCG maintenance therapy).

[0110] In some embodiments, the success of the method of treatment is determined by an improvement any disease-free survival (aDFS) as compared to standard of care (SoC) or a BCG treatment (i.e., a BCG induction therapy and / or a BCG maintenance therapy).[OHl] In some embodiments, the success of the method of treatment is determined by an improvement in time to MIBC and / or metastatic disease as compared to standard of care (SoC) or a BCG treatment (i.e., a BCG induction therapy and / or a BCG maintenance therapy).

[0112] In some embodiments, the success of the method of treatment is determined by an improvement in time to cystectomy as compared to standard of care (SoC) or a BCG treatment (i.e., a BCG induction therapy and / or a BCG maintenance therapy).

[0113] Thus, success of treatment may be defined as an increase in DFS, DFS12, DFS24, DFS36, CRR, OS, and / or OS5, in patients treated with the combination therapy as disclosed herein. Thus, an aspect of the disclosure may be methods, combination therapies for use, and uses disclosed herein for increasing DFS, DFS 12, DFS24, DFS36, CRR, OS, and / or OS5, preferably compared to SoC or a control or a BCG treatment (i.e., a BCG induction therapy and / or a BCG maintenance therapy). In some embodiments, the method, combination therapy for use, or use results in improvement in one or more of DFS, DFS 12, DFS24, DFS36, CRR, OS, and / or OS5, compared to a standard of care or a control, or a BCG treatment (i.e., a BCG induction therapy and / or a BCG maintenance therapy). In certain embodiments, the method, combination therapy for use, or use results in improvement in one or more of DFS, DFS12, DFS24, DFS36, CRR, OS, and / or OS5, compared to a BCG treatment alone (i.e., a BCG induction therapy and / or a BCG maintenance therapy).

[0114] In some embodiments of the methods disclosed herein, the combination treatment results in an improvement in disease-free survival (DFS) as compared to a standard of care or a control or a BCG treatment (i.e., a BCG induction therapy and / or a BCG maintenance therapy). In some embodiments, the methods result in an improvement in one or more of DFS, DFS12, DFS24, or DFS36 of at least about 4%, 5%, 6%, 7%, 8%, 9%, 10% or moreAttorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265compared to a standard of care or a control or a BCG treatment (i.e., a BCG induction therapy and / or a BCG maintenance therapy). In some embodiments, an improvement refers to an improvement or increase in DFS of at least about 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months or more compared to standard of care or a control or a BCG treatment (i.e., a BCG induction therapy and / or a BCG maintenance therapy). In some embodiments, the methods disclosed herein result in a DFS of at least about 50 months, 55 months, 60 months, 65 months, 70 months, 75 months, 80 months, 85 months, or more. In some embodiments, an improvement refers to an improvement or increase in DFS compared to standard of care or a control or a BCG treatment (i.e., a BCG induction therapy and / or a BCG maintenance therapy). In some embodiments, the improvement in DFS is a statistically significant and / or a clinically meaningful improvement.

[0115] In some embodiments of the methods disclosed herein, the method results in an improvement in overall survival (OS) as compared to a standard of care or a control or a BCG treatment (i.e., a BCG induction therapy and / or a BCG maintenance therapy). In some embodiments, an improvement refers to an improvement or increase in OS of at least about 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months or more compared to standard of care or a control or a BCG treatment (i.e., a BCG induction therapy and / or a BCG maintenance therapy). In some embodiments, the methods disclosed herein result in an OS at least about 50 months, 55 months, 60 months, 65 months, 70 months, 75 months, 80 months, 85 months, or more. In some embodiments, an improvement refers to an improvement or increase in OS compared to standard of care or a control or a BCG treatment (i.e., a BCG induction therapy and / or a BCG maintenance therapy). In some embodiments, the improvement in OS is a statistically significant and / or a clinically meaningful improvement.

[0116] As used herein, the term "standard of care" (SoC) can refer to one or more of BCG treatment and / or BCG treatment in combination with TURBT. BCG treatment, in combination with TURBT, is the current NCCN and European Society for Medical Oncology guideline-recommended standard of care for high-risk NMIBC (National Comprehensive Cancer Network 2016; Bellmunt et al 2014).

[0117] As used herein, the terms "disease-free survival" and "DFS" refer to the time from the date of randomization until the date of first recurrence of high-risk disease or death (by any cause in the absence of recurrence) regardless of whether the patient withdraws from randomized therapy or receives another anticancer therapy prior to high-risk recurrence. In some embodiments, the following would constitute a recurrence event of high-risk disease: a)Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265recurrence of high-risk NMIBC (high-grade Ta, Tl, or CIS), b) presentation with MIBC and / or metastatic disease; or c) persistent CIS at 6 months. In some embodiments, recurrence of low / medium risk NMIBC will not be considered as recurrence of high-risk of disease. For patients who have persistent CIS at 6 months, they will be counted as experiencing DFS event at Day 1. In some embodiments, patients who have not experienced high-risk disease recurrence or died at the time of analysis will be censored at the time of the latest date of assessment from their last evaluable disease assessment. However, if the patient experiences high-risk recurrence or dies after 2 or more consecutive missed visits, the patient will be censored at the time of the latest evaluable disease assessment prior to the consecutive missed visits. If the patient has no evaluable visits or does not have baseline data, they will be censored at Day 1 unless they die within 2 visits from baseline. The DFS time will always be derived based on disease assessment dates and not visit dates.

[0118] As used herein, the terms "disease-free survival at 12 months" and "DFS 12" refer to the proportion of patients alive and disease free at 12 months after randomization. The DFS12 will be defined as the Kaplan-Meier estimate of DFS at 12 months after randomization.

[0119] As used herein, the terms "disease-free survival at 24 months" and "DFS24" refer to the proportion of patients alive and disease free at 24 months after randomization. The DFS24 will be defined as the Kaplan-Meier estimate of DFS at 24 months after randomization.

[0120] As used herein, the terms "disease-free survival at 36 months" and "DFS36" refer to the proportion of patients alive and disease free at 36 months after randomization. The DFS36 will be defined as the Kaplan-Meier estimate of DFS at 36 months after randomization.

[0121] As used herein, the terms "complete response rate" or "CRR" refer to the proportion of patients having CIS prior to study entry or at baseline cystoscopy who do not have CIS at six months. The denominator for CRR will be patients having CIS prior to study entry or at baseline cystoscopy.

[0122] As used herein, the terms "overall survival" and "OS" refer the proportion of patients alive from the date of randomization until death due to any cause. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive. In order to minimize confounding of OS, patients randomized to BCG alone will not be allowed to cross over to the other treatment group (BCG in combination with durvalumab). In some embodiments, survival calls will be madeAttorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265following the date of data cutoff for the analysis (these contacts should generally occur within 7 days of the data cutoff). In some embodiments, if patients are confirmed to be alive or if the death date is post the data cutoff date, these patients will be censored at the date of data cutoff. Death dates may be found by checking publicly available death registries, where allowed by local regulations. In some embodiments, the OS5 will be defined as the Kaplan-Meier estimate of OS at 5 years after randomization. OS5 will be summarized using the same methodology as DFS24.

[0123] As used herein, the terms "any disease-free survival" and "aDFS" refer to DFS as defined above, except that aDFS includes recurrence of low / medium risk NMIBC. In some embodiments, aDFS in the ITT population will be analyzed using stratified log-rank tests, using the same methodology as described for the primary DFS endpoint. The effect of treatment will be estimated by the HR together with its corresponding 95% CI for the ITT population. Kaplan-Meier plots will be presented by treatment group.

[0124] Time to MIBC and / or metastatic disease refer to the time from the date of randomization until the date of first documented MIBC and / or metastatic disease. Time to MIBC and / or metastatic disease does not include deaths. If patients died without MIBC and / or metastatic disease, they will be censored at the time of death. Time to MIBC and / or metastatic disease in the ITT population will be analyzed using the same methodology as described for aDFS.

[0125] Time to cystectomy refers to the time from the date of randomization until the date of cystectomy. Patients who died prior to cystectomy will be censored at the time of death. Time to cystectomy will be analyzed using the same methodology as described for aDFS.

[0126] Time to development of upper tract urothelial carcinoma (TTUTUC) refers to the time from the date of randomization until the date of development of upper tract urothelial carcinoma. TTUTUC does not include deaths. If patients died without upper tract urothelial carcinoma, they will be censored at the time of death. TTUTUC will be analyzed using the same methodology as described for aDFS.

[0127] The terms "administration" or "administering" as used herein refer to providing, contacting, and / or delivering a compound or compounds by any appropriate route to achieve the desired effect. Administration may include, but is not limited to, oral, sublingual, parenteral (e.g., intravenous, subcutaneous, intracutaneous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional, or intracranial injection), transdermal, topical, buccal, rectal, vaginal, nasal, ophthalmic, via inhalation, and implants. In certain embodiments, administration of the durvalumab is intravenous (IV).Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265

[0128] It is to be understood that the particular aspects of the specification are described herein are not limited to specific embodiments presented, and can vary. It also will be understood that the terminology used herein is for the purpose of describing particular aspects only and, unless specifically defined herein, is not intended to be limiting. Moreover, particular embodiments disclosed herein can be combined with other embodiments disclosed herein, as would be recognized by a skilled person, without limitation.

[0129] Without limiting the disclosure, a number of embodiments of the disclosure are described below for purpose of illustration.EMBODIMENTSEmbodiment 1 : A method of treating a patient identified as having non-muscle-invasive bladder cancer (NMIBC), the method comprising administering to the patient a combination therapy comprising a PD-L1 antibody and a bacillus Calmette-Guerin (BCG) treatment, wherein the PD-L1 antibody is administered about every 28 days (Q4W).Embodiment 2: A method of increasing disease-free survival (DFS) and / or overall survival (OS) in a patient with non-muscle-invasive bladder cancer (NMIBC), the method comprising administering to the patient a combination therapy comprising a PD-L1 antibody and a bacillus Calmette-Guerin (BCG) treatment.Embodiment 3 : The method of either embodiment 1 or embodiment 2, wherein the PD- L1 antibody is durvalumab, adebrelimab (SHR-1316), atezolizumab, avelumab, cosibelimab (CK-301), envafolimab, or sugemalimab (CS1001).Embodiment 4: The method of any one of embodiments 1-3, wherein the PD-L1 antibody is durvalumab.Embodiment 5: The method of embodiment 2, wherein the PD-L1 antibody is administered about every 28 days (Q4W).Embodiment 6: The method of any one of embodiments 1-5, wherein the BCG treatment is a BCG induction therapy administered about every 7 days (Q1W) for about 6 weeks.Embodiment 7: The method of any one of embodiments 1-5, wherein the PD-L1 antibody is administered about every 28 days (Q4W) for about 13 cycles or up to about 13 cycles.Embodiment 8: The method of any one of embodiments 1-7 further comprising administering a BCG maintenance therapy.Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265Embodiment 9: The method of embodiment 8, wherein the BCG maintenance therapy comprises administering the BCG therapy at 3 months, 6 months, 12 months, 18 months, and 24 months.Embodiment 10: The method of embodiment 8, wherein the BCG maintenance therapy comprises administering the BCG treatment about every 7 days for three consecutive weeks at about 3 months, 6 months, 12 months, 18 months, and 24 months.Embodiment 11 : The method of any one of embodiments 1-10, wherein the PD-L1 antibody of the combination therapy comprises about 1000 to 2000 mg of durvalumab.Embodiment 12: The method of any one of embodiments 1-11, wherein the PD-L1 antibody of the combination therapy comprises about 1500 mg of durvalumab.Embodiment 13 : A method of treating a patient identified as having non -muscle-invasive bladder cancer (NMIBC), the method comprising:(i) administering to the patient about 1500 mg of durvalumab about every 4 weeks (Q4W) for about 13 cycles;(ii) administering to the patient a bacillus Calmette-Guerin (BCG) induction therapy about every 7 days (Q1W) for about 6 weeks; and(iii) administering to the patient a BCG maintenance therapy about every 7 days for three consecutive weeks at about 3 months, 6 months, 12 months, 18 months, and 24 months.Embodiment 14: The method of any one of embodiments 1-13, wherein the NMIBC is a high-risk tumor.Embodiment 15: The method of embodiment 14, wherein the high-risk tumor is defined as one or more of the following:(i) a T1 tumor;(ii) a high grade / G3 tumor;(iii) carcinoma in situ (CIS); and(iv) multiple, and recurrent, and large (tumor diameter >3 cm) tumors.Embodiment 16: The method of any one of embodiments 1-15, wherein the method results in improvement in DFS and / or overall survival (OS) compared to the BCG induction therapy alone and / or the BCG induction therapy and the BCG maintenance therapy.Embodiment 17: The method of any one of embodiments 1-16, wherein the method results in a significant improvement in disease-free survival (DFS); and optionally an improvement in one or more of:(i) disease-free survival at 12 months (DFS 12) of at least about 5%;Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265(ii) disease-free survival at 24 months (DFS24) of at least about 5%;(iii) disease-free survival at 36 months (DFS36) of at least about 4% or 5%; and (vi) overall survival (OS).Embodiment 18: A combination therapy comprising a PD-L1 antibody and a bacillus Calmette-Guerin (BCG) treatment for use in treating non-muscle-invasive bladder cancer (NMIBC) in a patient in need thereof, wherein the PD-L1 antibody is administered about every 28 days (Q4W).Embodiment 19: A combination therapy comprising a PD-L1 antibody and a bacillus Calmette-Guerin (BCG) treatment for use in increasing disease-free survival (DFS) and / or overall survival (OS) in a patient with non-muscle-invasive bladder cancer (NMIBC).Embodiment 20: The combination therapy for the use of either embodiment 18 or embodiment 19, wherein the PD-L1 antibody is durvalumab, adebrelimab (SHR-1316), atezolizumab, avelumab, cosibelimab (CK-301), envafolimab, or sugemalimab (CS1001). Embodiment 21 : The combination therapy for the use of any one of embodiments 18-20, wherein the PD-L1 antibody is durvalumab.Embodiment 22: The combination therapy for the use of embodiment 19, wherein the PD-L1 antibody is administered about every 28 days (Q4W).Embodiment 23: The combination therapy for the use of any one of embodiments 18-22, wherein the BCG treatment of the combination therapy is a BCG induction therapy administered about every 7 days (Q1W) for about 6 weeks.Embodiment 24: The combination therapy for the use of any one of embodiments 18-23, wherein the PD-L1 antibody of the combination therapy is administered about every 28 days (Q4W) for about 13 cycles or up to about 13 cycles.Embodiment 25: The combination therapy for the use of any one of embodiments 18-24 further comprising administering a BCG maintenance therapy.Embodiment 26: The combination therapy for the use of embodiment 25, wherein the BCG maintenance therapy comprises administering the BCG treatment about every 7 days for three consecutive weeks at about 3 months, 6 months, 12 months, 18 months, and 24 months.Embodiment 27: The combination therapy for the use of any one of embodiments 18-26, wherein the PD-L1 antibody of the combination therapy comprises about 1000 to 2000 mg of durvalumab.Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265Embodiment 28: The combination therapy for the use of any one of embodiments 18-27, wherein the PD-L1 antibody of the combination therapy comprises about 1500 mg of durvalumab.Embodiment 29: A combination therapy for use in treating a patient identified as having non-muscle-invasive bladder cancer (NMIBC), wherein the combination therapy comprises:(i) administering to the patient about 1500 mg of durvalumab about every 4 weeks (Q4W) for about 13 cycles;(ii) administering to the patient a bacillus Calmette-Guerin (BCG) induction therapy about every 7 days (Q1W) for about 6 weeks; and(iii) administering to the patient a BCG maintenance therapy about every 7 days for three consecutive weeks at about 3 months, 6 months, 12 months, 18 months, and 24 months.Embodiment 30: The combination therapy for the use of any one of embodiments 18-29, wherein the NMIBC is a high-risk tumor.Embodiment 31 : The combination therapy for the use of embodiment 30, wherein the high-risk tumor is defined as one of the following:(i) a T1 tumor;(ii) a high grade / G3 tumor;(iii) carcinoma in situ (CIS); and(iv) multiple, and recurrent, and large (tumor diameter >3 cm) tumors (all conditions must be met in this point).Embodiment 32: The combination therapy for the use of any one of embodiments 18-31, wherein the use of the combination therapy results in improvement in DFS and / or OS compared to the BCG induction therapy alone and / or the BCG induction therapy and the BCG maintenance therapy.Embodiment 33: The combination therapy for the use of any one of embodiments 18-33, wherein the use of the combination therapy results in a significant improvement in disease-free survival (DFS); and optionally an improvement in one or more of:(i) disease-free survival at 12 months (DFS 12) of at least about 5%;(ii) disease-free survival at 24 months (DFS24) of at least about 5%;(iii) disease-free survival at 36 months (DFS36) of at least about 4% or 5%; and (vi) overall survival (OS).Embodiment 34: The use of a combination therapy comprising a PD-L1 antibody and a bacillus Calmette-Guerin (BCG) treatment for the manufacture of a medicament for treatingAttorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265non-muscle-invasive bladder cancer (NMIBC) in a patient in need thereof, wherein the PD-L1 antibody of the medicament is administered about every 28 days (Q4W).Embodiment 35: The use of a combination therapy comprising a PD-L1 antibody and a bacillus Calmette-Guerin (BCG) treatment for the manufacture of a medicament for increasing disease-free survival (DFS) and / or overall survival (OS) in a patient with non-muscle-invasive bladder cancer (NMIBC).Embodiment 36: The use of either embodiment 34 or embodiment 35, wherein the PD- L1 antibody is durvalumab, adebrelimab (SHR-1316), atezolizumab, avelumab, cosibelimab (CK-301), envafolimab, or sugemalimab (CS1001).Embodiment 37: The use of any one of embodiments 34-36, wherein the PD-L1 antibody is durvalumab.Embodiment 38: The use of embodiment 35, wherein the PD-L1 antibody is administered about every 28 days (Q4W).Embodiment 39: The use of any one of embodiments 34-38, wherein the BCG treatment of the medicament is a BCG induction therapy administered about every 7 days (Q1W) for about 6 weeks.Embodiment 40: The use of any one of embodiments 34-39, wherein the PD-L1 antibody of the medicament is administered about every 28 days (Q4W) for about 13 cycles or up to about 13 cycles.Embodiment 41 : The use of any one of embodiments 34-40 further comprising administering a BCG maintenance therapy.Embodiment 42: The use of embodiment 41, wherein the BCG maintenance therapy comprises administering the BCG therapy about every 7 days for three consecutive weeks at about 3 months, 6 months, 12 months, 18 months, and 24 months.Embodiment 43 : The use of any one of embodiments 34-42, wherein the PD-L1 antibody of the medicament comprises about 1000 to 2000 mg of durvalumab.Embodiment 44: The use of any one of embodiments 34-43, wherein the PD-L1 antibody of the medicament comprises about 1500 mg of durvalumab.Embodiment 45: The use of a durvalumab and a bacillus Calmette-Guerin (BCG) treatment in the manufacture of a medicament for treating non-muscle-invasive bladder cancer (NMIBC) in a combination therapy, wherein the combination therapy comprises:(i) administering to the patient about 1500 mg of durvalumab about every 4 weeks (Q4W) for about 13 cycles;Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265(ii) administering to the patient a bacillus Calmette-Guerin (BCG) induction therapy about every 7 days for about 6 weeks; and(iii) administering to the patient a BCG maintenance therapy about every 7 days for three consecutive weeks at about 3 months, 6 months, 12 months, 18 months, and 24 months.Embodiment 46: The use of any one of embodiments 34-45, wherein the NMIBC is a high-risk tumor.Embodiment 47: The use of embodiment 46, wherein the high-risk tumor is defined as one of the following:(i) a T1 tumor;(ii) high grade / G3 tumor;(iii) carcinoma in situ (CIS); and(iv) multiple, and recurrent, and large (tumor diameter >3 cm) tumors.Embodiment 48: The use of any one of embodiments 34-47, wherein the use of the combination therapy results in improvement of DFS and / or OS compared to the BCG induction therapy alone and / or the BCG induction therapy and the BCG maintenance therapy. Embodiment 49: The use of any one of embodiments 34-48, wherein the use of the combination therapy results in a significant improvement in disease-free survival (DFS); and optionally an improvement in one or more of:(i) disease-free survival at 12 months (DFS 12) of at least about 5%;(ii) disease-free survival at 24 months (DFS24) of at least about 5%;(iii) disease-free survival at 36 months (DFS36) of at least about 4% or 5%; and (vi) overall survival (OS).EXAMPLES

[0130] Example 1 - A Phase III Randomized, Open-Label, Multi-Center, Global Study of Durvalumab and Bacillus Calmette-Guerin (BCG) Administered as Combination Therapy Versus BCG Alone in High-Risk, BCG-Naive Non-Muscle-Invasive Bladder Cancer Patients (POTOMAC).

[0131] Study Design. This study screens patients with high-risk, non-muscle-invasive bladder cancer (NMIBC) who have had no prior systemic therapy or Bacillus Calmette-Guerin (BCG) intravesical therapy for bladder cancer. The study is a Phase III, randomized, open-label, multi-center, global study to determine the efficacy and safety of durvalumab + BCG (induction and maintenance; I+M) combination therapy and durvalumab + BCG (inductionAttorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265only; I) combination therapy versus BCG (induction and maintenance) alone in the treatment of patients 18 years of age or older with a histologically confirmed diagnosis of high-risk NMIBC who have received no prior systemic therapy for NMIBC and who are BCG-naive (i.e., patients who have not received prior intravesical BCG or who previously received but stopped intravesical BCG more than 3 years before study entry are eligible).

[0132] A high-risk tumor is defined as one of the following: a tumor invading the lamina propria (Tl); a high grade or histologic grade (G)3 tumor; CIS; or multiple, recurrent, and large (with diameter of largest tumor >3 cm) tumors (all conditions must be met in this point).

[0133] Patients will be randomized in a 1:1:1 ratio to one of the following three treatment groups (the overall study design is presented in Figure 1).

[0134] (1) Durvalumab + BCG (induction and maintenance; I+M) combination therapy treatment group (see Arm A in FIG.1):• Durvalumab (1500 mg intravenously 13 cycles every 4 weeks [Q4W]) unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion, including high-risk disease persistence, high-risk disease recurrence, or disease progression, is met. (Note If a patient’s weight falls to 30 kg or below (<30 kg), then the patient should receive weight-based dosing equivalent to 20 mg / kg of durvalumab Q4W, after consultation between the Investigator and Study Physician, until the weight improves to above 30 kg (>30 kg), at which point the patient should start receiving the fixed dosing of durvalumab 1500 mg Q4W).• BCG induction therapy with 1 vial of BCG (e.g. TICE® BCG) administered intravesically weekly for 6 weeks. Dose reductions will be permitted according to local standard dose.• BCG maintenance therapy with 1 vial of BCG (e.g. TICE® BCG) administered intravesically for 3 weekly doses at 3, 6, 12, 18, and 24 months (i.e. once about every 7 days for three consecutive weeks at months 3, 6, 12, 18, and 24). Local guidance should be observed for BCG during supply shortages, with a potential for a reduced dose or adjusted schedule of maintenance cycles. If a strain other than TICE® BCG (for majority of countries), Tokyo, or BCG-1 (for Japan and Russia) is considered, the local physician must discuss and receive approval from the Sponsor to use the selected strain.Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265• For patients with persistent CIS disease at 3 months, a single BCG re-induction must be administered weekly for 6 weeks followed by BCG maintenance that will be administered for 3 weekly doses at 6, 12, 18, and 24 months. If patients demonstrate BCG failure (do not demonstrate complete response) after re-induction, they must be discontinued from treatment.

[0135] (2) Durvalumab + BCG (induction only; I) combination therapy treatment group (see Arm B in FIG.1):• Durvalumab (1500 mg intravenously 13 cycles [Q4W]).• BCG induction only with 1 vial of BCG (e.g. TICE® BCG) administered intravesically weekly for 6 weeks.• For patients with persistent CIS disease at 3 months, a single BCG re-induction must be administered weekly for 6 weeks. If patients demonstrate BCG failure (do not demonstrate complete response) after re-induction, they must be discontinued from treatment.

[0136] (3) BCG (induction and maintenance; I+M) alone treatment group (see Arm C in FIG.l):• BCG induction only with 1 vial of BCG (e.g. TICE® BCG) administered intravesically weekly for 6 weeks.• BCG maintenance with 1 vial of BCG (e.g. TICE® BCG) administered intravesically for 3 weekly doses at 3, 6, 12, 18, and 24 months (i.e. once about every 7 days for three consecutive weeks at months 3, 6, 12, 18, and 24). Local guidance should be observed for BCG during supply shortages, with a potential for a reduced dose or adjusted schedule of maintenance cycles. If a strain other than TICE® (for majority of countries), Tokyo, or BCG-1 (for Japan and Russia) is considered, the local physician must discuss and receive approval from the Sponsor to use the selected strain.• For patients with persistent CIS disease at 3 months, a single BCG re-induction must be administered weekly for 6 weeks followed by BCG maintenance that will be administered for 3 weekly doses at 6, 12, 18, and 24 months. If patients demonstrate BCG failure (do not demonstrate complete response) after re-induction, they must be discontinued from treatment, and the Investigator will determine appropriate subsequent treatments.Table 3: Treatment regimens overviewCohort BCG dose and regimenaDurvalumab doseand regimenAttorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265Durvalumab + BCG Induction: 1 vial of BCG (e.g. TICE® BCG) Durvalumab 1500 (induction and administered intravesically weekly for 6 weeks mg Q4W from maintenance) Week 1 (±3 days) combination therapy Maintenance: 1 vial of BCG (e.g. TICE® BCG) for 13 cycles treatment group administered intravesically for 3 weekly doses at 3,6, 12, 18, and 24 months.Local guidance should be observed for BCG duringshortages, with a potential for a reduced dose oradjusted schedule of maintenance cycles.Durvalumab + BCG Induction: 1 vial of BCG (e.g. TICE® BCG) Durvalumab 1500 (induction only) administered intravesically weekly for 6 weeks. mg Q4W from combination therapy Week 1 (±3 days) treatment group for 13 cycles BCG (induction and Induction: 1 vial of BCG (e.g. TICE® BCG) NA maintenance) alone administered intravesically weekly for 6 weeks.treatment groupMaintenance: 1 vial of BCG (e.g. TICE® BCG) administered intravesically for 3 weekly doses at 3,6, 12, 18, and 24 months.Local guidance should be observed for BCG duringshortages, with a potential for a reduced dose oradjusted schedule of maintenance cycles.Note: For patients with persistent CIS disease at 3 months, a single BCG re-induction must be administered weekly for 6 weeks according to local standard practice. For patients assigned to receive BCG (induction and maintenance) as part of their assigned treatment regimen, re-induction will be followed by BCG maintenance that will be administered for 3 weekly doses at 6, 12, 18, and 24 months. If patients demonstrate BCG failure (do not demonstrate complete response) after re-induction, they must be discontinued from treatment, and the investigator will determine appropriate subsequent treatments.Note: Patients whose weight falls to <30 kg must receive weight-based dosing for durvalumab (as applicable) - equivalent to 20 mg / kg of durvalumab - until the weight improves to >30 kg, at which point the patient should resume taking the fixed dosing of durvalumab (1500 mg).Note: If durvalumab dosing is delayed, the BCG treatment regimen will be maintained, and the total number of doses of durvalumab (13) will be maintained unless criteria for discontinuation of IP are met. In the case of dose delay of durvalumab, patients may receive a total of 13 doses of durvalumab, and it is acceptable for these doses to extend beyond the originally planned durvalumab treatment period. Patients may delay and subsequently resume BCG dosing per local standard clinical practice. If dosing must be delayed for reasons other than treatment-related toxicity, dosing will resume as soon as feasible. BCG dose delays will not affect durvalumab dosing.Note: If durvalumab dosing is discontinued, patients will be permitted to continue on BCG. If BCG is discontinued, patients will be allowed to continue durvalumab treatment at the discretion of the treating PI.Note: Durvalumab and BCG may be administered on the same day; durvalumab would be administered first, followed by BCG.BCG Bacillus Calmette-Guerin; NA Not applicable; PI Principal Investigator; Q4W Every 4 weeksaOther BCG strains may be selected for use if TICE® BCG is not available (e.g. Tokyo for Japanand BCG-1 for Russia).

[0137] The objectives of this Phase III study are summarized in Table 4.Table 4. Objectives of the studyAttorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265Primary objectives: Outcome measure:To assess the efficacy of durvalumab + Disease-free survival using Investigator Bacillus Calmette -Guerin (BCG) disease assessments(induction and maintenance) combinationtherapy compared to BCG (induction andmaintenance) aloneSecondary objectives: Outcome measures:To assess the efficacy of durvalumab + BCG Proportion of patients alive and disease free at (induction and maintenance) combination 24 months using Investigator disease therapy compared to BCG (induction and assessments Overall survival at 5 years maintenance) aloneAny disease-free survival using Investigator disease assessmentsTime to MIBC and / or metastatic disease using Investigator disease assessments Time to cystectomy using Investigator disease assessmentsTime to development of upper tract urothelial carcinoma using Investigator disease To assess the efficacy of durvalumab + BCG Disease-free survival using Investigator (induction only) combination therapy disease assessmentscompared to BCG (induction and Proportion of patients alive and disease free at maintenance) alone 24 months using Investigator disease assessments Overall survival at 5 years Any disease-free survival using Investigator disease assessmentsTime to MIBC and / or metastatic disease using Investigator disease assessments Time to cystectomy using Investigator disease assessmentsTime to development of upper tract urothelial carcinoma using Investigator disease To assess the efficacy of durvalumab + BCG Disease-free survival using Investigator (induction and maintenance) combination disease assessmentstherapy compared to durvalumab + BCG Proportion of patients alive and disease free at (induction only) 24 months using Investigator disease assessments Overall survival at 5 years Any disease-free survival using Investigator disease assessmentsTime to MIBC and / or metastatic disease using Investigator disease assessments Time to cystectomy using Investigator disease assessmentsTime to development of upper tract urothelial carcinoma using Investigator diseaseAttorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265To assess the efficacy of durvalumab + Complete response rate (CRR) at 6 months BCG combination therapy compared to using Investigator disease assessmentsBCG (induction and maintenance) forpatients with CIS prior to study entry or atbaseline cystoscopy.BCG = Bacillus Calmette-Guerin

[0138] Inclusion criteria. For inclusion in the study, patients should fulfill the following criteria:1. Age >18 years at the time of screening.2. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the Informed Consent Form (ICF) and in this protocol. Written informed consent and any locally required authorization (e.g., Health Insurance Portability and Accountability Act in the US, European Union [EU] Data Privacy Directive in the EU) obtained from the patient / legal representative prior to performing any protocol-related procedures, including screening evaluations. For patients aged <20 years and enrolling in Japan, a written informed consent should be obtained from the patient and his or her legally acceptable representative.3. BCG-naive (e.g. patients who have not received prior intravesical BCG or who previously received, but stopped BCG more than 3 years before study entry are eligible).4. Local histological confirmation (based on pathology report) of high-risk transitional cell carcinoma of the urothelium of the urinary bladder confined to the mucosa or submucosa. A high-risk tumor can be defined as one of the following:• T1 tumor• High grade / G3 tumor• CIS• Multiple and recurrent and large (with diameter of largest tumor >3 cm) tumors (all conditions must be met in this point).5. Complete resection of all Ta / Tl papillary disease prior to randomization, with the TURBT removing high-risk NMIBC performed not more than 4 months before randomization in the study. Patients with residual CIS after TURBT are eligible. 6. No prior radiotherapy for bladder cancer.Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-2657. World Health Organization (WHO) / Eastem Cooperative Oncology Group (ECOG) performance status of 0 or 1 at screening.8. Body weight >30 kg.9. Must have a life expectancy of at least 12 weeks.10. No prior exposure to immune-mediated therapy of cancer including, but not limited to, other anti CTLA-4, anti-PD-1, anti-PD-Ll, and anti -programmed cell death ligand 2 antibodies. Patients who have been treated with anticancer vaccines will be excluded.11. Must be a candidate for BCG treatment.12. Adequate organ and marrow function as defined below:• Hemoglobin >9.0 g / dL.• Absolute neutrophil count >1.0 x 109 / L.• Platelet count >75 * 109 / L.• Serum bilirubin <1.5 x the upper limit of normal (ULN). This will not apply to patients with confirmed Gilbert’s syndrome, who will be allowed in consultation with their physician.• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <2.5 x ULN.• Measured creatinine clearance (CL) >40 mL / min or calculated creatinine CL >40 mL / min as determined by Cockcroft-Gault (using actual body weight). • Males: Creatinine CL (mL / min) = (Weight (kg) x (140 - Age)) / (72 x serum creatinine (mg / dL).• Females: Creatinine CL = [(Weight (kg) x (140 - Age)) / (72 x serum creatinine (mg / dL))] x 0.85.13. Evidence of postmenopausal status or negative urinary (dipstick) or serum pregnancy test for female premenopausal patients. Women will be considered postmenopausal if they have been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:• Women <50 years of age would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone (LH) and follicle- stimulating hormone (FSH) levels in the postmenopausal range for theAttorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265institution or underwent surgical sterilization (bilateral oophorectomy or hysterectomy).• Women >50 years of age would be considered postmenopausal if they have been amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments, had radiation-induced menopause with last menses >1 year ago, had chemotherapy -induced menopause with last menses >1 year ago, or underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy or hysterectomy).14. At screening, provision of a tumor biopsy that is formalin-fixed and paraffin- embedded (FFPE) is mandatory. Tumor sample should be relevant to the high-risk NMIBC which is the reason for inclusion in the study, preferably, from TURBT removing this tumor.

[0139] Disease-free survival (DFS). DFS is defined as the time from the date of randomization until the date of first recurrence of high-risk disease or death (by any cause in the absence of recurrence) regardless of whether the patient withdraws from randomized therapy or receives another anticancer therapy prior to high-risk recurrence, per Investigator disease assessment. The following would constitute a recurrence event of high risk disease: a) recurrence of high-risk NMIBC (high-grade Ta, Tl, or CIS), b) presentation with MIBC and / or metastatic disease; or c) persistent CIS at 6 months. Note: Recurrence of low / medium risk NMIBC will not be considered as recurrence of high-risk of disease. For patients who have persistent CIS at 6 months, they will be counted as experiencing DFS event at Day 1. Patients who have not experienced high-risk disease recurrence or died at the time of analysis will be censored at the time of the latest date of assessment from their last evaluable disease assessment. However, if the patient experiences high-risk recurrence or dies after 2 or more consecutive missed visits, the patient will be censored at the time of the latest evaluable disease assessment prior to the consecutive missed visits. If the patient has no evaluable visits or does not have baseline data, they will be censored at Day 1 unless they die within 2 visits from baseline. The DFS time will always be derived based on disease assessment dates and not visit dates.

[0140] The analysis will be performed in the ITT population using a stratified log-rank test adjusting for higher risk papillary disease (yes versus no) and CIS (yes versus no). The effect of durvalumab + BCG (induction and maintenance) versus BCG (induction and maintenance) treatment alone will be estimated by the HR together with its corresponding ([1 -adjusted alpha] x 100%) CI and p-value.Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265

[0141] The HR and its CI will be estimated from the stratified Cox proportional hazards model (Cox 1972).

[0142] Attrition bias will be assessed by repeating the DFS analysis except that the actual DFS event times, rather than the censored times, of patients who had high-risk recurrence or died in the absence of high-risk recurrence immediately following 2 or more non-evaluable disease assessments will be included. In addition, within the same sensitivity analysis patients who take subsequent therapy (note that for this analysis radiotherapy is not considered a subsequent anticancer therapy) prior to their last evaluable assessment, high-risk recurrence, or death will be censored at their last evaluable assessment prior to taking the subsequent therapy. This analysis will be supported by a Kaplan-Meier plot of the time to censoring using the DFS data from the primary analysis and where the censoring indicator of the DFS analysis is reversed.

[0143] Subgroup analyses will be conducted comparing DFS between durvalumab + BCG combination therapy (induction ± maintenance) and BCG (induction and maintenance) alone in the following subgroups of the FAS including, but not limited to:• Sex (male versus female)• Age at randomization (<65 years versus >65 years)• CIS (yes versus no)• T1G3 / T1 high-grade (yes versus no)• Multiple and recurrent and large (with diameter of largest tumor >3 cm) tumors (yes versus no)• BCG strains• PD-L1 status (high versus low / neg) if data allows

[0144] PD-L1 status will be described in the SAP.

[0145] Secondary endpoints

[0146] Proportion of patients alive and disease free at 24 months after randomization (DFS24). The DFS24 will be defined as the Kaplan-Meier estimate of DFS at 24 months after randomization, per Investigator disease assessment.

[0147] DFS24 will be summarized (using the Kaplan -Mei er curve) and presented by treatment group. Each will be compared between treatments by using the Kaplan-Meier estimator of DFS at 24 months for each treatment to obtain the HR. The HR and CI will be presented using the following approach (Klein et al 2007).

[0148] The HR (group 1 :group2) is estimated as:Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265InS^tThe variance for hi(HR) is estimated as^i(t)2g(02ln2S1(t)+ln2S2(t)where «ft(t)2=dj *sthe variance for lnS(t) derived from Greenwood’s formula forthe variance of survival function S(t) and can be estimated from standard software packages, where dtand n refer to the number of events and patients at risk at time ft

[0149] A test statistic is then constructed as:(lii(ffR))7 aria n ce (in ( H R ) )

[0150] The ln(HR) and its variance in each strata are estimated and combined by weighting inversely proportionately according to each within stratum variance (Whitehead and Whitehead 1991). A chi-square test will be performed and the p-value from the test will be presented. The test statistic follows the Chi-square distribution with one degree of freedom under Ho (Klein et al 2007).

[0151] Complete response rate (CRR). CRR is defined as the proportion of patients having CIS prior to study entry or at baseline cystoscopy who do not have CIS at six months. The CRR will be based on Investigator assessment. The denominator for CRR will be patients having CIS prior to study entry or at baseline cystoscopy.

[0152] The proportion of patients will be compared between pooled durvalumab + BCG combination therapy and BCG alone using a logistic regression model adjusted for the stratification factors. The results of the analysis will be presented in terms of an odds ratio together with its corresponding 95% CI and p-value.

[0153] Proportion of patients alive at 5 years after randomization (OS5). OS is defined as the time from the date of randomization until death due to any cause. Any patient not known to have died at the time of analysis will be censored based on the last recorded date on which the patient was known to be alive. In order to minimize confounding of OS, patients randomized to BCG alone will not be allowed to cross over to the other treatment group (BCG in combination with durvalumab). Note: Survival calls will be made following the date of data cutoff for the analysis (these contacts should generally occur within 7 days of theAttorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265data cutoff). If patients are confirmed to be alive or if the death date is post the data cutoff date, these patients will be censored at the date of data cutoff. Death dates may be found by checking publicly available death registries, where allowed by local regulations. The OS5 will be defined as the Kaplan-Meier estimate of OS at 5 years after randomization. OS5 will be summarized using the same methodology as DFS24.

[0154] Any disease-free survival (aDFS). aDFS is defined similarly as DFS, except that aDFS includes recurrence of low / medium risk NMIBC. This will be based on Investigator disease assessments. aDFS in the ITT population will be analyzed using stratified log-rank tests, using the same methodology as described for the primary DFS endpoint. The effect of treatment will be estimated by the HR together with its corresponding 95% CI for the ITT population. Kaplan-Meier plots will be presented by treatment group.

[0155] Time to MIBC and / or metastatic disease. Time to MIBC and / or metastatic disease is defined as the time from the date of randomization until the date of first documented MIBC and / or metastatic disease as assessed by Investigator. Time to MIBC and / or metastatic disease does not include deaths. If patients died without MIBC and / or metastatic disease, they will be censored at the time of death. Time to MIBC and / or metastatic disease in the ITT population will be analyzed using the same methodology as described for aDFS.

[0156] Time to cystectomy. Time to cystectomy is defined as the time from the date of randomization until the date of cystectomy as assessed by Investigator. Patients who died prior to cystectomy will be censored at the time of death. Time to cystectomy will be analyzed using the same methodology as described for aDFS.

[0157] Time to development of upper tract urothelial carcinoma (TTUTUC). TTUTUC is defined as the time from the date of randomization until the date of development of upper tract urothelial carcinoma as assessed by Investigator; TTUTUC does not include deaths. If patients died without upper tract urothelial carcinoma, they will be censored at the time of death. TTUTUC will be analyzed using the same methodology as described for aDFS.

[0158] Results

[0159] Approximately 1,000 patients were randomized in a 1 : 1 : 1 ratio to one of three treatment groups. The overall study design is presented in Figure 1, and patient disease characteristics, disposition, and demographics are shown in Tables 5-7, respectively.Table 5. Patient Disease CharacteristicsDisease D + BCG (I+M) D + BCG (I) BCG (I+M) Characteristics (N=339) (N=339) (N=340)Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265CIS only Yes 31 (9.1) 34 (10.0) 30 (8.8)No 308 (90.9) 305 (90.0) 310 (91.2) Papillary tumor only Yes 217 (64.0) 222 (65.5) 220 (64.7)No 122 (36.0) 117 (34.5) 120 (35.3)CIS and Papillary Yes 91 (26.8) 83 (24.5) 90 (26.5)tumor No 248 (73.2) 256 (75.5) 250 (73.5)Table 6. Patient DispositionPatient Disposition D + BCG D + BCG BCG (I+M)(I+M) (I) (N=340) (N=339) (N=339)Patients randomized, n (%) 339 (100.0) 339 (100.0) 340 (100.0) Patients who received study treatment, n (%) 336 (99.1) 337 (99.4) 339 (99.7) Patients who discontinued study treatment, n (%) 336 (100.0) 337 (100.0) 339 (100.0) Subject decision 45 (13.4) 13 (3.9) 22 (6.5) Adverse event 61 (18.2) 38 (11.3) 74 ( 21.8) Development of study specific discontinuation 31 (9.2) 37 (11.0) 52 (15.3) criteria 1 (0.3) 0 0 Subject lost to follow-up 180 (53.6) 182 (53.7) 239 (70.9) Completed 2 (0.6) 1 (0.3) 8 (2.4) Due to COVID-19 pandemic 16 (4.8) 8 (2.4) 2 (0.6) OtherPatients ongoing study at data cut off, n (%) 270 (79.6) 272 (80.2) 263 (77.4)Table 7. Demographic CharacteristicsD + BCG (I+M) D + BCG (I) BCG (I+M) (N=339) (N=339) (N=340) Age (years) Median (range) 68.0 (24-90) 68.0 (21-87) 67.0 (32-86) Age group <50 20 (5.9) 23 (6.8) 18 (5.3) (years), n(%) >=50 - <65 101 (29.8) 100 (29.5) 119 (35.0)>=65 - <75 144 (42.5) 150 (44.2) 131 (38.5) >=75 74 (21.8) 66 (19.5) 72 (21.2) Sex, n (%) Male 276 (81.4) 272 (80.2) 271 (79.7)Female 63 (18.6) 67 (19.8) 69 (20.3) Race, n (%) White 267 (78.8) 267 (78.8) 268 (78.8)Black or African 0 1 (0.3) 1 (0.3) AmericanAsian 61 (18.0) 63 (18.6) 60 (17.6) Native Hawaiian or other 0 1 (0.3) 0 Pacific IslanderOther 4 (1.2) 4 (1.2) 7 (2.1)Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265Efficacy Summary

[0160] The study was well-conducted, recruited the expected patient population and was balanced across arms. The control arm outperformed the protocol assumptions.

[0161] The study’s final analysis demonstrated a statistically significant and clinically meaningful improvement in disease free survival (DFS) for Durvalumab + BCG (I+M) versus BCG (I+M) for patients with BCG naive, high-risk non-muscle invasive bladder cancer (see Figure 4 and Table 8; HR 0.68 (96.83% CI 0.48, 0.96), p=0.0154, 24% maturity). Durvalumab + BCG (I+M) reduced the risk of high-risk disease recurrence, progression, or death by 32% in the ITT population compared to BCG (I+M).

[0162] The results also demonstrate an improvement in overall survival (OS), with no OS detriment with HR 0.80 (95% CI 0.53, 1.20), p=0.2816 with a maturity of 14% [OS framework: green zone HR < 1, grey zone HR >1.0 - < 1.081] (see Figure 5 and Table 9).

[0163] No CRR benefit observed at 6 months; however high bar set by BCG alone: 93.4% vs 93.3%, OR 1.02 (95% CI 0.37, 2.81), p=0.9727.Efficacy and Safety Summary in Patients with Papillary Disease

[0164] In the ITT population, the proportion of patients with papillary disease without CIS was 64% in the D+BCG arm and 65% in the BCG (I+M) arm (see Table 5). Of these patients, 63% and 66% had T1 tumors only, respectively. The risk of a DFS event (defined as recurrence of high-risk disease or death) for the D+BCG (I+M) versus BCG (I+M) arm was reduced in patients with papillary disease only (44% reduction, HR 0.56, 95% CI 0.37-0.84), T1 tumors only (52% reduction, HR 0.48, 95% CI 0.28-0.79), and T1 disease ± CIS (n=195, D+BCG [I+M] arm; n=211, BCG [I+M] arm; 45% reduction, HR 0.55, 95% CI 0.36-0.83). HRs for OS were 0.68 (95% CI 0.42-1.09) for papillary disease only and 0.67 (95% CI 0.39-1.14) for T1 disease ± CIS.

[0165] Fewer high-risk events (high-risk NMIBC recurrence [high-grade Ta / Tl / CIS], persistent CIS at 6 months, or MIBC / metastasis) occurred with D+BCG (I+M) (53 / 339) versus BCG (I+M) (69 / 340). Median time to high-risk event was 14.1 vs 8.3 months; 45% (24 / 53) vs 61% (42 / 69) of patients had early high-risk events (<1 year from randomization). At recurrence, 65% (24 / 37; D+BCG [I+M]) versus 81% (44 / 54; BCG [I+M]) of patients met BCG-unresponsive criteria. Time to cystectomy resulted in a HR of 0.63 (95% CI 0.31-1.24) with D+BCG (I+M) versus BCG (I+M); median time to cystectomy was 19.0 vs 14.1 months (see Figure 7 and Table 14). The cystectomy-free survival HR was 0.69 (95% CI 0.48-0.99) with D+BCG (I+M) vs BCG (I+M) (see Figure 8). Outcomes in papillary subgroups areAttorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265summarized in Table 10, and safety in patients with papillary tumors was consistent with the overall population.Table 8. Results of DFS D+BCG (I+M) vs. BCG (I+M)D + BCG (I+M) BCG (I+M)(N=339) (N=340)Total DFS events, n (%) 67 98(20) (29)Median DFS, months NR NR(95% CI) (NR -NR) (74.0 - NR)HR 0.68(96.83% CI) (0.50 - 0.93)p-value 0.0154DFS36 (%) 82 77(95% CI) (77.0, 85.7) (72.4, 81.6)Median Duration of Follow-up 60.6 60.8(censored), months (Range) (0.03-78.9) (0.03-77.7)Table 9. OS in D+BCG (I+M) vs. BCG (I+M)D + BCG (I+M) BCG (I+M)(N=339) (N=340)Death, n (%) 41 52(12%) (15%)Median OS (months) NR NR(95% CI) (NR, NR) (NR, NR)HR 0.80(95% CI), (0.53 - 1.20)Log-rank p-value 0.2816Median Duration of Follow-up 65.6 65.9(Censored), months (Range) (0.1 - 81.0) (0.6- 80.3)Table 10. Outcomes in papillary subgroupsDisease Free Survival (DFS) Overall survival (OS) D+BCG (I+M) vs BCG (I+M) D+BCG (I+M) vs BCG (I+M) Subgroup Reduction in risk Hazard ratio Reduction in risk Hazard ratio of disease (95% CI) of death (95% CI) recurrence,progression ordeathAny papillary 39% 0.61 (0.43-0.85) 25% 0.76 (0.49-1.16) diseasePapillary disease 44% 0.56 (0.37-0.84) 32% 0.68 (0.42-1.09) onlyAnyTl 45% 0.55 (0.36-0.83 33% 0.67 (0.39-1.14) T1 only 52% 0.48 (0.28-0.79) 48% 0.52 (0.27-0.93) T1 high grade 45% 0.55 (0.31-0.94) 42% 0.58 (0.29-1.12)HR <1 favors D+BCG (I+M) vs BCG (] 1+M).Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265Table 11. Time to High-Risk Disease EventD+BCG (I+M) BCG (I+M)N=339 N=340Patients with high-risk 53 (16) 69 (20)disease event3, n (%)Time fromrandomization to high- risk disease event3,bMedian overall, months 14.1 8.3<3 months, n (%) 7 / 53 (13) 14 / 69 (20)<6 months, n (%) 14 / 53 (26) 29 / 69 (42)<12 months, n (%) 24 / 53 (45) 42 / 69 (61)a Descriptive analysis.b Includes patients who experience high-risk events as per DFS, except death.BCG, bacillus Calmette -Guerin; CIS, carcinoma in situ; D, durvalumab; I, induction; M, maintenance; MIBC, muscle invasive bladder cancer; NMIBC, non-muscle invasive bladdercancer.

[0166] The majority of patients received adequate BCG therapy. Most patients with high-risk NMIBC recurrence or persistent CIS met BCG unresponsive criteria, with fewer BCG unresponsive recurrences in D+BCG (I+M) vs BCG (I+M) arms. Addition of durvalumab to BCG (I+M) did not impact patients’ ability to receive adequate BCG therapy. Almost double the number of BCG unresponsive disease events occurred in the BCG (I+M) arm compared with the D+BCG (I+M) arm (see Table 12 and Table 13).Table 12. Receipt of adequate BCG therapyD+BCG (I+M) BCG (I+M)n=336 n=339Patients with adequate BCG therapy, n (%) 291 (87) 315 (93)Adequate BCG therapy requires >5 out of 6 induction doses and >2 out of 3maintenance doses or >2 out of 6 doses of second induction course.Table 13. BCG unresponsive diseaseD+BCG (I+M) BCG (I+M) N=339 N=340High-risk NMIBC recurrence (high grade Ta, 37 / 339 ( 1 1) 54 / 340 ( 16) T1 or CIS) or persistent CIS, n / N (%)BCG unresponsive, n (%) 24 / 37 (65) 44 / 54 (82) BCG unresponsive disease defined per US FDA guidelines: After adequate BCG (I+M):Pcrsistcnt / rccurrcnt CIS ± recurrent Ta / Tl disease within 12 months or: Recurrent high-gradeTa / Tl disease within 6 months or: T1 high-grade disease at first evaluation following BCG (I).Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265

[0167] Time to Cystectomy: Time to cystectomy showed a trend in favor of durvalumab + BCG (I+M) vs BCG (I+M), with fewer patients undergoing cystectomy, and a longer median time to cystectomy, compared with BCG (I+M) alone (see Figure 7 and Table 14). Fewer cystectomies were performed in the D+BCG (I+M) arm compared with the BCG (I+M) arm; this was also observed in patients with BCG unresponsive disease: in the D+BCG (I+M) arm 2 / 24 (8%) of patients underwent cystectomy, and in the BCG (I+M) arm 11 / 44 (25%) of patients underwent cystectomy. Additionally, cystectomy-free survival showed a favorable trend for D+BCG (I+M) vs BCG (I+M) (see Figure 8).Table. 14 Time to cystectomy (ITT population)3D+BCG (I+M) BCG (I+M)N=339 N=340Cystectomy events, n (%) 13 (4) 21 (6)Median, months (95% CI) NR (NR-NR) NR (NR-NR)HR (95% CI) 0.63 (0.31-1.24)

[0168] In patients with any papillary tumors or with papillary tumors only, there was a 39% and 44% reduction, respectively, in the risk of disease recurrence, progression or death with D+BCG (I+M) vs BCG (I+M) (see Figure 9), and in patients with T1 disease, there was a 45-52% reduction in the risk of disease recurrence, progression or death with D+BCG (I+M) vs BCG (I+M) (see Figure 10). Furthermore, the addition of durvalumab to BCG (I+M) had no detriment to overall survival across papillary tumor subgroups (see Figure 11).

[0169] D+BCG (I+M) prevented early high-risk disease recurrences, with fewer BCG-unresponsive recurrences. While the majority of patients with high-risk NMIBC recurrence or persistent CIS met the BCG unresponsive criteria, there were fewer BCG unresponsive recurrences with D+BCG (I+M) vs BCG (I+M). Time to cystectomy and cystectomy-free survival showed a trend in favor of D+BCG (I+M) vs BCG (I+M), and DFS benefit was observed across papillary tumor subgroups with D+BCG (I+M). These data further support D+BCG (I+M) as a potential new treatment in this setting.Safety Summary

[0170] The results show a higher incidence of max G3-4, SAEs, and immune mediated AEs (imAE; Pl-assessed) were observed with addition of Durvalumab to BCG (I+M). Adverse events (AEs) leading to discontinuation of any study treatment was higher in Durvalumab + BCG vs. BCG possibly due to contribution of both agents.Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265

[0171] Durvalumab + BCG (I+M) demonstrated a tolerable and manageable safety profile that is consistent with the individual agents and disease under investigation. The results demonstrate no new safety concerns. Addition of Durvalumab did not impact exposure to BCG and did not increase BCG toxicity.

[0172] The majority of AEs were low-grade and non-serious. There were no AEs with outcome of death, possibly related to treatment in any arm. Most common AEs in Durva + BCG (I+M) were similar to BCG (I+M) and consistent with the individual agents’ safety profiles and underlying disease.

[0173] Higher incidence of max G3-4, SAEs, and AEs leading to discontinuation were observed in Durva + BCG (I+M) vs BCG. This is consistent with the known Durvalumab safety profile and did not suggest new safety concerns.

[0174] Consistent with Durvalumab Mechanism of Action, imAEs (Pl-assessed) were higher in D+BCG (I+M) (39.0%) compared to BCG (I+M) (1.8%). The majority of imAEs were low grade. The most common were hypothyroidism, hepatitis, and hyperthyroidism - consistent with the known Durvalumab safety profile.Table 15. Adverse Event Summary (SAS)AE Category , n (%) D + BCG (I+M) D + BCG (I) BCG (I+M)(N=336) (N=337) (N=339) Any AE 325 (96.7) 322 (95.5) 307 (90.6) bePossibly related to study treatment 298 (88.7) 269 (79.8) 245 (72.3) Maximum CTCAE Grade 3 or 4 113 (33.6) 90 (26.7) 56 (16.5) Maximum CTCAE Grade 3 or 4, possibly 71 (21.1) 52 (15.4) 13 (3.8) berelated to study treatmentAny AE with outcome = death 6 (1.8) 4 (1.2) 4 (1.2) Any AE with outcome of death, possibly 0 0 0 berelated to study treatmentAny SAE 108 (32.1) 82 (24.3) 63 (18.6)beAny SAE possibly related to study treatment 45 (13.4) 38 (11.3) 13 (3.8) Any AE leading to discontinuation of study 105 (31.3) 65 (19.3) 68 (20.1) treatmentAny AE leading to discontinuation of study 54 (16.1) 44 (13.1) 1 (0.3) btreatment, possibly related to durvalumabAny AE leading to discontinuation of study 55 (16.4) 15 (4.5) 55 (16.2) btreatment, possibly related to BCGImmune mediated AEs 131 (39.0) 136 (40.4) 6 (1.8)Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265a Includes adverse events with an onset date on or after the date of first dose or pre -treatment AEs that increase in severity on or after the date of first dose up to and including 90 days following the date of last dose or study medication or up to and including the date of initiation of the first subsequent therapy (whichever occurs first), b As assessed by the investigator. Missing responses are counted as related.c For combination arm, AEs are counted as related if related to Durvalumab or related to BCG or missing response for either treatment.d As assessed by the investigator.

[0175] In patients with papillary disease only, grade 3 / 4 treatment-related adverse events (AEs) occurred in 23% (49 / 215; D+BCG [I+M]) and 3% (6 / 219; BCG [I+M]) of patients.Immune-mediated AEs (imAEs) occurred in 27% (58 / 215) with D+BCG (I+M), with 9% (20 / 215) experiencing a maximum grade 3 / 4 event, with 60% (35 / 58) of those events resolved / resolving. Durvalumab in combination with BCG (I+M) provided a significant and clinically meaningful benefit in patients with papillary disease, including those with T1 tumors only and T1 ± CIS disease. The safety profile was consistent with that of the overall population (see Figure 12). The safety profile of D+BCG (I+M) in patients with papillary tumors was consistent with that observed in the overall safety population, and imAEs were mostly low grade and manageable, and consistent with the known safety profile of durvalumab (see Figure 13). Of patients who experienced imAEs, 66% had imAEs resolved (with or without sequalae) or resolving at the time of data cutoff (see Figure 14). Safety reported in each papillary tumor subgroup was consistent with that seen in the papillary tumors only subgroup.REFERENCES

[0176] Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76.

[0177] Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SAJR, Behjati S, Blankin AV, et al. Signatures of mutational processes in human cancer. Nature 2013 Aug 22;500:415-21.

[0178] American Cancer Society 2016. American Cancer Society. Bladder cancer. 2016.Available from: URL: http: / / www.cancer.org / cancer / bladdercancer / . Accessed 10 May 2017.

[0179] Anastasiadis A, de Reijke TM. Best practice in the treatment of nonmuscle invasive bladder cancer. Ther Adv Urol 2012;4:13-32.

[0180] AUA Guidelines, http: / / www.auanet.org / guidelines / intravesical-administration-of-therapeutic-medication (accessed 22 June 2017).Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265

[0181] Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bbhle A, Palou J. European Association of Urology guidelines on TaTl (non-muscle invasive) bladder cancer. Update March 2008. Arnhem, the Netherlands: European Association of Urology; 2008.

[0182] Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Comperat E, et al. European Association of Urology: EAU guidelines on nonmuscle-invasive urothelial carcinoma of the bladder: Update 2013. Eur Urol 2013;64(4):639-53.

[0183] Babjuk M, Bbhle A, Burger M, Capoun O, Cohen D, Comperat E, et al. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016. Eur Urol 2017;71(3):447-461.

[0184] Barry MJ, Fowler FJ Jr, O’Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. Journal of Urology, 1992;148(5): 1549-1557

[0185] Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, et al. Adverse symptom event reporting by patients vs clinicians: relationship with clinical outcomes. Journal of National Cancer Institute 2009;101:1624-1632

[0186] BAVENCIO [package insert], New York, USA. 2017

[0187] BAVENCIO [Summary Product Characteristics], Middlesex TW14 8NX, UK. 2018.

[0188] Bellmunt J, Orsola A, Leow JJ, Wiegel T, De Santis M, Horwich A; ESMO Guidelines Working Group. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014 Sep;25 Suppl 3:iii40-8.

[0189] Bellmunt J, Powles T, Vogelzang N. A review on the evolution of PD-1 / PD-L1 immunotherapy for bladder cancer: The future is now. Cancer Treat Rev 2017;54:58-67.

[0190] Bidnur S, Savdie R, Black PC. Inhibiting immune checkpoints for the treatment of bladder cancer. Bladder Cancer 2016;2(l): 15-25.

[0191] Blazeby JM, Hall E, Aaronson NK, Lloyd L, Water, R, Kelly JD, and Fayers P.Validation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient- reported outcomes in non-muscle-invasive bladder cancer. European urology, 2014;66(6):l 148-1156.

[0192] Boccardo F, Palmeri L. Adjuvant chemotherapy of bladder cancer. Ann Oncol 2006;17(Suppl 5):vl29-32.

[0193] Brahmer JR, Tykodi SS, Chow LQM, Hwu WJ, Topalian SL, Hwu P, etal. Safety and activity of anti-PD-Ll antibody in patients with advanced cancer. N Engl J Med 2012 Jun;366(26):2455-65.Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265

[0194] Brausi M, Witjes JA, Lamm D, Persad R, Palou J, Colombel M et al. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group. J Urol 2011;186(6):2158-67.

[0195] Burman CF, Sonesson C, Guilbaud O. A recycling framework for the construction of Bonferroni-based multiple tests. Stat Med 2009;28(5):739-61.

[0196] Cambier S, Sylvester RJ, Collette L, Gontero P, Brausi MA, van Andel G, et al.EORTC nomograms and risk groups for predicting recurrence, progression, and diseasespecific and overall survival in non-muscle-invasive stage Ta-Tl urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette-Guerin. Eur Urol 2016 Jan;69(l):60-9.

[0197] Celia DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol 1993;11:570-9.

[0198] Cox DR. Regression models and life-tables. J Royal Stat Society 1972; Series B 34(2): 187-220.

[0199] Danna BJ, Metcalf MJ, Wood EL, Shah JB. Assessing symptom burden in bladder cancer: an overview of bladder cancer specific health-related quality of life instruments. BI Cancer 2016;2(3):329-40.

[0200] De Jager R, Guinan P, Lamm D, Khanna O, Brosman S, DeKernion J, et al. Longterm complete remission in bladder carcinoma in situ with intravesical TICE Bacillus Calmette Guerin. Urology 1991;38:507-13.

[0201] Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004;22:329-60.

[0202] Eble JN, Sauter G, Epstein JI, Sesterhenn IA, editors. Pathology and genetics of tumours of the urinary system and male genital organs. Lyon: IARCPRESS; 2004.(Available upon request).

[0203] EuroQol Group 1990. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 16(3): 199-208.

[0204] Fairman D, Narwal R, Liang M, Robbins PB, Schneider A, Chavez C, et al.Pharmacokinetics of durvalumab, a fully human anti-PDLl monoclonal antibody, in patients with advanced solid tumours. 2014 ASCO Annual Meeting Abstracts. J Clin Oncol 2014;32(5s) (suppl;abstr 2602).Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265

[0205] Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A; EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual. 3rd ed. Brussels: European Organisation for Research and Treatment of Cancer: 2001.

[0206] FDA 2017. Food and Drug Administration. Approved Drugs. Available from: URL: https: / / www.fda.gov / drugs / informationondrugs / approveddrugs / ucm279174.htm. Accessed 17 May 2017.

[0207] Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86.

[0208] Fuge O, Vasdev N, Allchorne P, Green J. Immunotherapy for bladder cancer. Res Rep Urol 2015;7:65-79.

[0209] Gail M, Simon R. Testing for qualitative interactions between treatment effects and patient subsets. Biometrics. 1985;41 (2):361 -72.

[0210] Gibney GT, Kudchadkar RR, DeConti RC, Thebeau MS, Czupryn MP, Tetteh L, et al. Safety, correlative markers, and clinical results of adjuvant nivolumab in combination with vaccine in resected high-risk metastatic melanoma. Clin Cancer Res 2015;21(4):712-20.

[0211] Gill DM, Sonpavde G, Pal SK, Agarwal N. Which checkpoint inhibitor? An embarrassment of riches forbladder cancer. Immunotherapy. 2017;9(6):463-466.

[0212] GLOBOCAN 2012. World Health Organization. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide 2012. Available at: URL: http: / / globocan.iarc.fr / Pages / fact_sheets_cancer.aspx.

[0213] Griffin JG, Holzbeierlein J. Side effects of perioperative intravesical treatment and treatment strategies for these side effects. Urol Clin North Am. 2013;40(2): 197-210.

[0214] Herdman M, Gudex C, Lloyd A et al. Development and preliminary testing of the new five- level version of EQ-5D (EQ-5D-5L). Qual Life Res: 1-10; 2011 Dec;20(10): 1727-36.

[0215] Herr HW, Dalbagni G. Defining bacillus Calmette-Guerin refractory superficial bladder tumours. J Urol. 2003;169:1706-8.

[0216] Hinotsu S, Kamatani N, Ratliff TL, Akaza H. A systematic review and meta-analysis on the safety and efficacy of different strains of Mycobacterium bovis bacillus Calmette-Guerin for non-muscle invasive bladder cancer in Japan and US. Eur J Oncology Pharmacy 2014;8(4):8-I8.Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265

[0217] Hirano F, Kaneko K, Tamura H, Dong H, Wang S, Ichikawa M, et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res 2005;65(3): 1089-96.

[0218] Hwang I, Shih W, De Cani J. Group sequential designs using a family of type I error probability spending functions. Stat Med 1990;9:1439-1445.

[0219] IMFINZI [package insert], Cambridge, England. 2017

[0220] Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 2002;99:12293-7.

[0221] Jakse G, Loidl W, Seeber G, Hofstadter F. Stage Tl, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumor? J Urol 1987; 137(l):39-43.

[0222] Jennison C, Turnbull BW. Mid-course sample size modification in clinical trials based on the observed treatment effect. Stat Med 2003;22(6):971-93.

[0223] Kamat AM, Sylvester RJ, Bbhle A, Palou J, Lamm DL, Brausi M, et al. Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International Bladder Cancer Group. J Clin Oncol 2016;34(16):1935-44.

[0224] Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677-704.

[0225] KEYTRUD A [package insert], New Jersey, USA. 2014.

[0226] KEYTRUDA [Summary Product Characteristics], Hertfordshire EN11 9BU, UK. 2017.

[0227] Kim K, DeMets DL. Design and analysis of group sequential tests based on the type I error spending rate function. Biometrika. 1987;74(1): 149-54.

[0228] Klein JP, Logan B, Harhoff M, Andersen PK. Analyzing survival curves at a fixed point in time. Stat Med 2007;26(24):4505-19.

[0229] Lamm DL, van der Meijden PM, Morales A, Brosman SA, Catalona WJ, Herr HW. Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer. J Urol 1992;147(3):596-600.

[0230] Lamm D, Colombel M, Persad, R, Soloway M, Bohle A, Palou J, et al. Clinical Practice Recommendations for the Management of Non-Muscle Invasive Bladder Cancer. European Urology Supplements 2008;7(10): 651-666.Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265

[0231] Lamm DL, Colombel M, Persad R, Soloway M, Bohle A, Palou J, et al. Clinical practice recommendations for the management of non-muscle invasive bladder cancer. Eur Urol Suppl 2008;7:651-66.

[0232] Lamm DL. BCG immunotherapy for transitional-cell carcinoma in situ of the bladder. Oncology 1995;9(10):947-52, 955-65.

[0233] Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983;70:659-63.

[0234] Lerner SP, Tangen CM, Sucharew H, Wood D, Crawford ED. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk nonmuscle invasive bladder cancer. Urol Oncol 2009;27(2): 155-9.

[0235]

[0236] Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, et al. Summary and Recommendations from the National Cancer Institute’s Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bl Cancer 2016;2(2): 165-202.

[0237] Litwin MS, Lubeck DP, Henning JM, et al. Differences in urologist and patient assessments of health related quality of life in men with prostate cancer: Results of the CaPSURE database. JUrol 1998;159:1988-92.

[0238] Liu ZH, Zheng FF, Mao YL, Ye LF, Bian J, Ye YL, et al. Effects of programmed death- ligand 1 expression on OK -432 immunotherapy following transurethral resection in non-muscle invasive bladder cancer. Oncol Lett 2017;13(6): 4818-24.

[0239] Lundholm C, Norlen BJ, Ekman P, Jahnson S, Lagerkvist M, Lindeborg T, et al. A randomized prospective study comparing long-term intravesical instillations of mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. J Urol 1996; 156 (2 Pt l):372-6.

[0240] Massard C, Gordon M, Sharma S, Rafii S, Wainberg Z, Luke J, et al. Safety and efficacy of Durvalumab (MEDI4736), an anti -programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer. J Clin Oncol 2016;34(26):3119-25.

[0241] Montoya L Managing Hematologic Toxicities in the Oncology Patient. JIN, 2007;30(3): 168-172.Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265

[0242] Narwal R, Roskos LK, Robbie GJ. Population pharmacokinetics of sifalimumab, an investigational anti-interferonalpha monoclonal antibody, in systemic lupus erythematosus. Clin Pharmacokinet 2013;52:1017-27.

[0243] National Comprehensive Cancer Network 2016. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology. Bladder Cancer. Version 2.2016. Available from: URL: https: / / www.nccn.org / professionals / physician_gls / pdf / bladder.pdf. Accessed 06 September 2016.

[0244] NCT023625942017. Study of pembrolizumab (MK-3475) versus placebo after complete resection of high-risk stage III melanoma (MK-3475-054 / KEYNOTE-054). https: / / www.clinicaltrials.gov. Accessed 16 August 2017.

[0245] NCT023889062017. Efficacy study of nivolumab compared to ipilimumab in prevention of recurrence of melanoma after complete resection of stage Illb / c or stage IV melanoma (CheckMate 238). https: / / www.clinicaltrials.gov. Accessed 16 August 2017.

[0246] NCT02506153 2017. High-dose recombinant interferon alfa-2B, ipilimumab, or pembrolizumab in treating patients with stage III-IV high risk melanoma that has been removed by surgery, https: / / www.clinicaltrials.gov. Accessed 16 August 2017.

[0247] NCT027921922017. Safety and pharmacology study of atezolizumab alone and in combination with Bacille Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer (NMIBC) participants, https: / / www.clinicaltrials.gov. Accessed 16 August 2017.

[0248] NCT02808143 2017. Pembrolizumab and BCG solution in treating patients with recurrent non-muscle-invasive bladder cancer, https: / / www.clinicaltrials.gov. Accessed 16 August 2017.

[0249] Ng CM, Lum BL, Gimenez V, Kelsey S, Allison D. Rationale for fixed dosing of pertuzumab in cancer patients based on population pharmacokinetic analysis. Pharm Res 2006;23(6): 1275-84.

[0250] Nunez-Nateras R, Castle EP, Protheroe CA, Stanton ML, Ocal TI, Ferri gni EN, et al. Predicting response to bacillus Calmette-Guerin (BCG) in patients with carcinoma in situ of the bladder. Urol Oncol 2014;32(l):45.e23-30.

[0251] Oddens J, Brausi M, Sylvester R, Bono A, van de Beek C, van Andel G et al. 2013 Final Results of an EORTC-GU Cancers Group Randomized Study of Maintenance Bacillus Calmette-Guerin in Intermediate- and High-risk Ta, Tl Papillary Carcinoma of the Urinary Bladder: One-third Dose Versus Full Dose and 1 Year Versus 3 Years of Maintenance. Euro Urol 2013 Mar;63(3):462-72.Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265

[0252] Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol. 2007; 19(7):813-24.

[0253] Okudaira K, Hokari R, Tsuzuki Y, Okada Y, Komoto S, Watanabe C, et al. Blockade of B7- Hl or B7-DC induces an anti-tumor effect in a mouse pancreatic cancer model. Int J Oncol 200935(4):741-9.

[0254] OPDI VO [package insert]. New Jersey, USA. 2014.

[0255] OPDIVO [Summary Product Characteristics], Middlesex, UB8 1DH, UK. 2017.

[0256] Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12:252-64.

[0257] Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014 Nov 27;515(7528):558-62.

[0258] Qin A, Coffey DG, Warren EH, Ramnath N. Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer. Cancer Med. 2016; 9:2169-2170.

[0259] Rawls WH, Lamm DL, Lowe BA, Crawford ED, Sarosdy MF, Montie JE, et al. Fatal sepsis following intravesical bacillus Calmette-Guerin administration for bladder cancer. J Urol 1990;144:1328-30.

[0260] Rizvi N, Brahmer J, Ou S-H, Segal NH, Khleif SN, Hwu WJ. Safety and clinical activity of MED 14736, an anti-programmed cell death -ligand- 1 (PD-L1) antibody, in patients with nonsmall cell lung cancer (NSCLC). J Clin Oncol 2015;33:Abstract 8032.

[0261] Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum -based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016;387:1909-20.

[0262] Schrier BP, Hollander MP, van Rhijn BWG, Kiemeney LA, Witjes JA. Prognosis of muscle- invasive bladder cancer: difference between primary and progressive tumours and possible implications for therapy. Eur Urol 2004; 45:292-6.

[0263] SEER (Surveillance, Epidemiology, and End Results) Program [Internet], 2016 [cited 09 Aug 2016], Available from: URL: http: / / www.seer.cancer.gov.

[0264] Segal NH, Ou S-HI, Balmanoukian AS, Fury MG, Massarelli E, Brahmer JR, et al. Safety and efficacy of MEDI4736, an anti-PD-Ll antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort. J Clin Oncol 2015;33:Abstract 3011.Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265

[0265] Serretta V, Scalici Gesolfo C, Alonge V, Cicero G, Moschini M, Colombo R. Does the compliance to intravesical BCG differ between common clinical practice and international multicentric trials? Urol Int 2016;96(l):20-4.

[0266] Shelley MD, Court JB, Kynaston H, Wilt TJ, Fish RG, Mason M. Intravesical Bacillus Calmette-Guerin in Ta and T1 bladder cancer. Cochrane Database Syst Rev 2000;(4):CD001986.

[0267] Sprangers MA, Aaronson NK. The role of health care providers and significant others in evaluating the quality of life of patients with chronic disease: A review. J Clin Epidemiol. 1992;45:743-760.

[0268] Stewart R, Morrow M, Hammond SA, Mulgrew K, Marcus D, Poon E, et al.Identification and characterization of MEDI4736, an antagonistic anti-PD-Ll monoclonal antibody. Cancer Immunol Res 2015;3(9): 1052-62.

[0269] Stockle M, Aiken P, Engelmann U, Jacobi GH, Riedmiller H, Hohenfellner R.Radical cystectomy — often too late? Eur Urol 1987; 13(6):361- 367.

[0270] Sun X, Chen C. Comparison of Finkelstein's Method with the conventional approach for interval-censored data analysis. Stat Biopharm Res 2010;2(l):97-108.

[0271] Sylvester RJ, van der Meijden AP, Lamm DL. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168(5): 1964-70.

[0272] Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, etal. Predicting recurrence and progression in individual patients with stage Ta, T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49(3):466-5.

[0273] TECENTRIQ [package insert], California, USA. 2016.

[0274] TECENTRIQ [Summary Product Characteristics], Hertfordshire, AL7 1TW. 2017.

[0275] TICE BCG label. Roseland, NJ, US: Organon; 2009.

[0276] Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443-54.

[0277] Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.

[0278] Uyen T, Kim J, Chia D. Disseminated BCG: Complications of Intravesical Bladder Cancer Treatment. Case Reports in Medicine, June 12, 2014.Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265

[0279] van Rhijn BWG, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, et al.Recurrence and Progression of Disease in Non-Muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy. Eur Urol 2009;56(3):430-442.

[0280] Vegt PD, Debruyne FM, van der Meijden AP. Bacillus Calmette-Guerin in superficial bladder cancer: consensus and controversies. Eur Urol 1995;27(2):89-95.

[0281] Wang DD, Zhang S, Zhao H, Men AY, Parivar K. Fixed dosing versus body size based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol 2009;49(9): 1012-24.

[0282] Washbum D. Intravesical Antineoplastic Therapy Following Transurethral Resection of Bladder Tumors: Nursing Implications From the Operating Room to Discharge. Clin J Oncol Nurs 2007; 11(4):553-559.

[0283] Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, et al. Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab refractory or -naive melanoma. J Clin Oncol 2013;31(34):4311 -8.

[0284] Whitehead A, Whitehead J. A general parametric approach to the meta-analysis of randomized clinical trials. StatMed 1991 ; 10(11): 1665-77.

[0285] Witjes JA. Management of BCG failures in superficial bladder cancer: a review. Eur Urol 2006;49:790-7.

[0286] Zhang C, Wu S, Xue X, Li M, Qin X, Li W, et al. Anti-tumor immunotherapy by blockade of the PD-1 / PD-L1 pathway with recombinant human PD-l-IgV. Cytotherapy 2008; 10(7):711-9.

[0287] Zhang S, Shi R, Li C, Parivar K, Wang DD. Fixed dosing versus body size-based dosing of therapeutic peptides and proteins in adults. J Clin Pharmacol 2012;52(l): 18-28.

Claims

Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265CLAIMSClaim 1 : A method of treating a patient identified as having non-muscle-invasive bladder cancer (NMIBC), the method comprising administering to the patient a combination therapy comprising a PD-L1 antibody and a bacillus Calmette-Guerin (BCG) treatment, wherein the PD-L1 antibody is administered about every 28 days (Q4W).Claim 2: A method of increasing disease-free survival (DFS) and / or overall survival (OS) in a patient with non-muscle-invasive bladder cancer (NMIBC), the method comprising administering to the patient a combination therapy comprising a PD-L1 antibody and a bacillus Calmette-Guerin (BCG) treatment.Claim 3: The method of either claim 1 or claim 2, wherein the PD-L1 antibody is durvalumab, adebrelimab (SHR-1316), atezolizumab, avelumab, cosibelimab (CK-301), envafolimab, or sugemalimab (C SI 001).Claim 4: The method of any one of claims 1-3, wherein the PD-L1 antibody is durvalumab.Claim 5: The method of claim 2, wherein the PD-L1 antibody is administered about every 28 days (Q4W).Claim 6: The method of any one of claims 1-5, wherein the BCG treatment is a BCG induction therapy administered about every 7 days (Q1W) for about 6 weeks.Claim 7: The method of any one of claims 1-5, wherein the PD-L1 antibody is administered about every 28 days (Q4W) for about 13 cycles or up to about 13 cycles.Claim 8: The method of any one of claims 1-7 further comprising administering a BCG maintenance therapy.Claim 9: The method of claim 8, wherein the BCG maintenance therapy comprises administering the BCG therapy at 3 months, 6 months, 12 months, 18 months, and 24 months.Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265Claim 10: The method of claim 8, wherein the BCG maintenance therapy comprises administering the BCG treatment about every 7 days for three consecutive weeks at about 3 months, 6 months, 12 months, 18 months, and 24 months.Claim 11 : The method of any one of claims 1-10, wherein the PD-L1 antibody of the combination therapy comprises about 1000 to 2000 mg of durvalumab.Claim 12: The method of any one of claims 1-11, wherein the PD-L1 antibody of the combination therapy comprises about 1500 mg of durvalumab.Claim 13 : A method of treating a patient identified as having non -muscle-invasive bladder cancer (NMIBC), the method comprising:(i) administering to the patient about 1500 mg of durvalumab about every 4 weeks (Q4W) for about 13 cycles;(ii) administering to the patient a bacillus Calmette-Guerin (BCG) induction therapy about every 7 days (Q1W) for about 6 weeks; and(iii) administering to the patient a BCG maintenance therapy about every 7 days for three consecutive weeks at about 3 months, 6 months, 12 months, 18 months, and 24 months.Claim 14: The method of any one of claims 1-13, wherein the NMIBC is a high-risk tumor.Claim 15: The method of claim 14, wherein the high-risk tumor is defined as one or more of the following:(i) a T1 tumor;(ii) a high grade / G3 tumor;(iii) carcinoma in situ (CIS);(iv) multiple, and recurrent, and large (tumor diameter >3 cm) tumors; and(v) having papillary disease with or without CIS.Claim 16: The method of any one of claims 1-15, wherein the method results in improvement in DFS and / or overall survival (OS) compared to the BCG induction therapy alone and / or the BCG induction therapy and the BCG maintenance therapy.58Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265Claim 17: The method of any one of claims 1-16, wherein the method results in a significant improvement in disease-free survival (DFS); and optionally an improvement in one or more of:(i) disease-free survival at 12 months (DFS 12) of at least about 5%;(ii) disease-free survival at 24 months (DFS24) of at least about 5%;(iii) disease-free survival at 36 months (DFS36) of at least about 4% or 5%; and (vi) overall survival (OS).Claim 18: A combination therapy comprising a PD-L1 antibody and a bacillus Calmette-Guerin (BCG) treatment for use in treating non-muscle-invasive bladder cancer (NMIBC) in a patient in need thereof, wherein the PD-L1 antibody is administered about every 28 days (Q4W).Claim 19: A combination therapy comprising a PD-L1 antibody and a bacillus Calmette-Guerin (BCG) treatment for use in increasing disease-free survival (DFS) and / or overall survival (OS) in a patient with non-muscle-invasive bladder cancer (NMIBC).Claim 20: The combination therapy of either claim 18 or claim 19, wherein the PD-L1 antibody is durvalumab, adebrelimab (SHR-1316), atezolizumab, avelumab, cosibelimab (CK-301), envafolimab, or sugemalimab (C SI 001).Claim 21 : The combination therapy of any one of claims 18-20, wherein the PD-L1 antibody is durvalumab.Claim 22: The combination therapy of claim 19, wherein the PD-L1 antibody is administered about every 28 days (Q4W).Claim 23 : The combination therapy for use of any one of claims 18-22, wherein the BCG treatment of the combination therapy is a BCG induction therapy administered about every 7 days (Q1W) for about 6 weeks.Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265Claim 24: The combination therapy for use of any one of claims 18-23, wherein the PD-L1 antibody of the combination therapy is administered about every 28 days (Q4W) for about 13 cycles or up to about 13 cycles.Claim 25: The combination therapy for use of any one of claims 18-24 further comprising administering a BCG maintenance therapy.Claim 26: The combination therapy for use of claim 25, wherein the BCG maintenance therapy comprises administering the BCG treatment about every 7 days for three consecutive weeks at about 3 months, 6 months, 12 months, 18 months, and 24 months.Claim 27: The combination therapy for use of any one of claims 18-26, wherein the PD-L1 antibody of the combination therapy comprises about 1000 to 2000 mg of durvalumab.Claim 28: The combination therapy for use of any one of claims 18-27, wherein the PD-L1 antibody of the combination therapy comprises about 1500 mg of durvalumab.Claim 29: A combination therapy for use in treating a patient identified as having nonmuscle-invasive bladder cancer (NMIBC), wherein the combination therapy comprises:(i) administering to the patient about 1500 mg of durvalumab about every 4 weeks (Q4W) for about 13 cycles;(ii) administering to the patient a bacillus Calmette-Guerin (BCG) induction therapy about every 7 days (Q1W) for about 6 weeks; and(iii) administering to the patient a BCG maintenance therapy about every 7 days for three consecutive weeks at about 3 months, 6 months, 12 months, 18 months, and 24 months.Claim 30: The combination therapy for use of any one of claims 18-29, wherein the NMIBC is a high-risk tumor.Claim 31 : The combination therapy for use of claim 30, wherein the high-risk tumor is defined as one of the following:(i) a T1 tumor;(ii) a high grade / G3 tumor;60Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265(iii) carcinoma in situ (CIS);(vi) multiple, and recurrent, and large (tumor diameter >3 cm) tumors (all conditions must be met in this point); and(iv) having papillary disease with or without CIS.Claim 32: The combination therapy for use of any one of claims 18-31, wherein the use of the combination therapy results in improvement in DFS and / or OS compared to the BCG induction therapy alone and / or the BCG induction therapy and the BCG maintenance therapy.Claim 33 : The combination therapy for use of any one of claims 18-32, wherein the use of the combination therapy results in a significant improvement in disease-free survival (DFS); and optionally an improvement in one or more of:(i) disease-free survival at 12 months (DFS 12) of at least about 5%;(ii) disease-free survival at 24 months (DFS24) of at least about 5%;(iii) disease-free survival at 36 months (DFS36) of at least about 4% or 5%; and (vi) overall survival (OS).Claim 34: The use of a combination therapy comprising a PD-L1 antibody and a bacillus Calmette-Guerin (BCG) treatment for the manufacture of a medicament for treating nonmuscle-invasive bladder cancer (NMIBC) in a patient in need thereof, wherein the PD-L1 antibody of the medicament is administered about every 28 days (Q4W).Claim 35: The use of a combination therapy comprising a PD-L1 antibody and a bacillus Calmette-Guerin (BCG) treatment for the manufacture of a medicament for increasing disease-free survival (DFS) and / or overall survival (OS) in a patient with non-muscle-invasive bladder cancer (NMIBC).Claim 36: The use of either claim 34 or claim 35, wherein the PD-L1 antibody is durvalumab, adebrelimab (SHR-1316), atezolizumab, avelumab, cosibelimab (CK-301), envafolimab, or sugemalimab (CS1001).Claim 37: The use of any one of claims 34-36, wherein the PD-L1 antibody is durvalumab.61Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265Claim 38: The use of claim 35, wherein the PD-L1 antibody is administered about every 28 days (Q4W).Claim 39: The use of any one of claims 34-38, wherein the BCG treatment of the medicament is a BCG induction therapy administered about every 7 days (Q1W) for about 6 weeks.Claim 40: The use of any one of claims 34-39, wherein the PD-L1 antibody of the medicament is administered about every 28 days (Q4W) for about 13 cycles or up to about 13 cycles.Claim 41 : The use of any one of claims 34-40 further comprising administering a BCG maintenance therapy.Claim 42: The use of claim 41, wherein the BCG maintenance therapy comprises administering the BCG therapy about every 7 days for three consecutive weeks at about 3 months, 6 months, 12 months, 18 months, and 24 months.Claim 43: The use of any one of claims 34-42, wherein the PD-L1 antibody of the medicament comprises about 1000 to 2000 mg of durvalumab.Claim 44: The use of any one of claims 34-43, wherein the PD-L1 antibody of the medicament comprises about 1500 mg of durvalumab.Claim 45: The use of a durvalumab and a bacillus Calmette-Guerin (BCG) treatment in the manufacture of a medicament for treating non-muscle-invasive bladder cancer (NMIBC) in a combination therapy, wherein the combination therapy comprises:(i) administering to the patient about 1500 mg of durvalumab about every 4 weeks (Q4W) for about 13 cycles;(ii) administering to the patient a bacillus Calmette-Guerin (BCG) induction therapy about every 7 days for about 6 weeks; and(iii) administering to the patient a BCG maintenance therapy about every 7 days for three consecutive weeks at about 3 months, 6 months, 12 months, 18 months, and 24 months.Attorney Ref.: 24-1098-WO; AZ Ref.: B7H1-265Claim 46: The use of any one of claims 34-45, wherein the NMIBC is a high-risk tumor.Claim 47: The use of claim 46, wherein the high-risk tumor is defined as one of the following:(i) a T1 tumor;(ii) high grade / G3 tumor;(iii) carcinoma in situ (CIS); and(iv) multiple, and recurrent, and large (tumor diameter >3 cm) tumors; and(v) having papillary disease with or without CIS.Claim 48: The use of any one of claims 34-47, wherein the use of the combination therapy results in improvement of DFS and / or OS compared to the BCG induction therapy alone and / or the BCG induction therapy and the BCG maintenance therapy.Claim 49: The use of any one of claims 34-48, wherein the use of the combination therapy results in a significant improvement in disease-free survival (DFS); and optionally an improvement in one or more of:(i) disease-free survival at 12 months (DFS 12) of at least about 5%;(ii) disease-free survival at 24 months (DFS24) of at least about 5%;(iii) disease-free survival at 36 months (DFS36) of at least about 4% or 5%; and (vi) overall survival (OS).